Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 18-21 March 2024
Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. Introduction 8
   1.1. Welcome and declarations of interest of members, alternates and experts ............... 8
   1.2. Adoption of agenda ................................................................................................ 8
   1.3. Adoption of the minutes ......................................................................................... 8

2. Oral Explanations 9
   2.1. Pre-authorisation procedure oral explanations ....................................................... 9
       2.1.1. Aprocitentan - EMEA/H/C/006080 .......................................................... 9
       2.1.2. Omecamtiv mecarbil - EMEA/H/C/006112 .............................................. 9
       2.1.3. Lecanemab - EMEA/H/C/005966 ............................................................ 9
   2.2. Re-examination procedure oral explanations ......................................................... 9
   2.3. Post-authorisation procedure oral explanations ................................................... 10
       2.3.1. Rinvoq - upadacitinib - EMEA/H/C/PSUSA/00010823/202302 ...................... 10
   2.4. Referral procedure oral explanations ................................................................... 10

3. Initial applications 10
   3.1. Initial applications; Opinions ................................................................................ 10
       3.1.1. AGILUS - Dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009 .... 10
       3.1.2. Awiqli - Insulin icodec - EMEA/H/C/005978 .............................................. 10
       3.1.3. Dimethyl fumarate Accord - Dimethyl fumarate - EMEA/H/C/006471 ............... 11
       3.1.4. Dimethyl fumarate Mylan - Dimethyl fumarate - EMEA/H/C/006397 ............... 11
       3.1.5. Dimethyl fumarate Neuraxpharm - Dimethyl fumarate - EMEA/H/C/006500 ........ 12
       3.1.6. Emblaveo - Aztreonam / Avibactam - EMEA/H/C/006113 ............................ 12
       3.1.7. Fabhalta - Iptacopan - PRIME - Orphan - EMEA/H/C/005764 ......................... 12
       3.1.8. Jubbonti - Denosumab - EMEA/H/C/005964 .............................................. 13
       3.1.9. Lytenava - Bevacizumab - EMEA/H/C/005723 ............................................ 13
       3.1.10. Neoatrichon - Dopamine hydrochloride - PUMA - EMEA/H/C/006044 .......... 14
       3.1.11. Onlylyco - Omalizumab - EMEA/H/C/005958 ........................................... 14
       3.1.12. Wyost - Denosumab - EMEA/H/C/006378 ............................................... 15
   3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ................................................................. 15
       3.2.1. Apadamtase alfa - Orphan - EMEA/H/C/006198 ........................................... 15
       3.2.2. Efanesoctocog alfa - Orphan - EMEA/H/C/005968 ....................................... 15
       3.2.3. Fidanacogene elaparvovec - PRIME - ATMP - EMEA/H/C/004774 ............... 16
       3.2.4. Buprenorphine - EMEA/H/C/006188 ......................................................... 16
       3.2.5. Dabigatran etexilate - EMEA/H/C/006023 .................................................. 16
       3.2.6. Dasatinib - EMEA/H/C/006251 ................................................................. 16
       3.2.7. Dasiglucagon - EMEA/H/C/006214 ............................................................ 17
3.2.8. Rituximab - EMEA/H/C/006224 ................................................................. 17
3.2.9. Aprocitentan - EMEA/H/C/006080 ......................................................... 17
3.2.10. Omecamtiv mecarbil - EMEA/H/C/006112 ........................................... 18
3.2.11. Lecanemab - EMEA/H/C/005966 ......................................................... 18
3.2.12. rdESAT-6 / rCFP-10 - EMEA/H/C/006177 ............................................. 18
3.2.13. Ustekinumab - EMEA/H/C/005918 ...................................................... 18
3.2.14. Zolbetuximab - Orphan - EMEA/H/C/005868 ........................................ 19

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) ............................................. 19
3.3.1. Garadacimab - Orphan - EMEA/H/C/006116 ......................................... 19
3.3.2. Aflibercept - EMEA/H/C/006056 .......................................................... 19
3.3.3. Beremagene geperpavec - PRIME - Orphan - ATMP - EMEA/H/C/006330 20

3.4. Update on on-going initial applications for Centralised procedure .......... 20
3.4.1. Tiratricol - Orphan - EMEA/H/C/005220 ................................................. 20
3.4.2. Leniolisib - Orphan - EMEA/H/C/005927 .............................................. 20
3.4.3. Masitinib - Orphan - EMEA/H/C/005897 .............................................. 20

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 ................................................................. 21

3.6. Initial applications in the decision-making phase .................................... 21

3.7. Withdrawals of initial marketing authorisation application ..................... 21

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 21

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion ................................................................. 21
4.1.1. AMGEVITA - Adalimumab - EMEA/H/C/004212/X/0036/G .................. 21
4.1.2. COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/019922 4.1.3. LUMYKRAS - Sotorasib - EMEA/H/C/005522/X/0009 ......................... 22

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues ................... 22
4.2.1. Reagila - Cariprazine - EMEA/H/C/002770/X/0033 .............................. 22
4.2.2. Spevigo - Spesolimab - EMEA/H/C/005874/X/0006/G ......................... 23
4.2.3. XALKORI - Crizotinib - EMEA/H/C/002489/X/0080/G ...................... 23

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question ......................... 24

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 ................................................................. 24
4.4.1. Eurartesim - Piperaquine tetrabiphosphate / Artenimol - EMEA/H/C/001199/X/0041 24
4.4.2. Opsumit - Macitentan - EMEA/H/C/002697/X/0051/G ....................... 24

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .................. 24
5. **Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008**

5.1. **Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information**

5.1.1. Alecensa - Alectinib - EMEA/H/C/004164/II/0047

5.1.2. Bimezlk - Bimekizumab - EMEA/H/C/005316/II/0020

5.1.3. CellCept - Mycophenolate mofetil - EMEA/H/C/000082/II/0170/G

5.1.4. Dupixent - Dupilumab - EMEA/H/C/004390/II/0081

5.1.5. Fasenra - Benralizumab - EMEA/H/C/004433/II/0052

5.1.6. IMCIVREE - Setmelanotide - Orphan - EMEA/H/C/005089/II/0018

5.1.7. Imfinzi - Durvalumab - EMEA/H/C/004771/II/0064

5.1.8. Kevzara - Sarilumab - EMEA/H/C/004254/II/0044

5.1.9. Kisqali - Ribocilcib - EMEA/H/C/004213/II/0045

5.1.10. Nilemdo - Bempedoic acid - EMEA/H/C/004958/II/0031

5.1.11. Nustendi - Bempedoic acid / Ezetimibe - EMEA/H/C/004959/II/0035

5.1.12. Onivyde pegylated liposomal - Irinotecan hydrochloride trihydrate - Orphan - EMEA/H/C/004125/II/0034

5.1.13. Otezla - Apremilast - EMEA/H/C/003746/II/0044/G

5.1.14. Pravafenix - Fenofibrate / Pravastatin sodium - EMEA/H/C/001243/II/0037

5.1.15. Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0022

5.1.16. RYBREVANT - Amivantamab - EMEA/H/C/005454/II/0011

5.1.17. Slenyto - Melatonin - EMEA/H/C/004425/II/0025

5.1.18. Triumeq - Dolutegravir / Abacavir / Lamivudine - EMEA/H/C/002754/II/0116

5.1.19. Vabysmo - Faricimab - EMEA/H/C/005642/II/0005

5.1.20. Valdoxan - Agomelatine - EMEA/H/C/000915/II/0051

5.1.21. Veklury - Remdesivir - EMEA/H/C/005622/II/0053/G

5.1.22. Xtandi - Enzalutamide - EMEA/H/C/002639/II/0063

5.2. **Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

5.3. **Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

6. **Medical devices**

6.1. **Ancillary medicinal substances - initial consultation**

6.2. **Ancillary medicinal substances – post-consultation update**

6.3. **Companion diagnostics - initial consultation**

6.3.1. In vitro diagnostic medical device - EMEA/H/D/006470

6.3.2. In vitro diagnostic medical device - EMEA/H/D/006454

6.4. **Companion diagnostics – follow-up consultation**
7. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 37

8. **Pre-submission issues**

8.1. Pre-submission issue 37

8.1.1. Sargramostim - H0006411 37

8.2. Priority Medicines (PRIME) 37

9. **Post-authorisation issues**

9.1. Post-authorisation issues 37

9.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0109 37

9.1.2. Cuprymina – copper (64Cu) chloride – EMEA/H/C/002136 38

9.1.3. Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0072, Orphan, ATMP 38

9.1.4. Ondexxya - Andexanet alfa - EMEA/H/C/004108/II/0044 38

9.1.5. Retsevmo - Selpaercatinib - EMEA/H/C/005375/II/0028 39

9.1.6. Rinvoq - upadacitinib - EMEA/H/C/PSUSA/00010823/202302 39


9.1.8. Remsima - Infliximab - EMEA/H/C/002576/II/0133/G 40

9.1.9. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675 41

10. **Referral procedures**


10.1.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065 41

10.1.2. Ocaliva - obeticholic acid - EMEA/H/A-20/1531 41

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 42

10.2.1. Colistimethate sodium (CMS) – EMEA/H/A-5(3)/1524 42

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 43

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) – under Article 29(4) of Directive 2001/83/EC 43

10.4.1. Micrazym – porcine pancreas enzymes - EMEA/H/A-29(4)/1535 43


10.5.1. Havrix – Hepatitis A virus (inactivated, adsorbed) - EMEA/H/A-30/1527 43


10.7.1. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529 44

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 ................................................................. 45
10.10. Procedure under Article 29 of Regulation (EC) 1901/2006................................. 45
10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 ................................................................. 45
10.11.1. Lorazepam Macure – lorazepam - EMEA/H/A-13/1536 ........................................ 45

11. Pharmacovigilance issue 46
11.1. Early Notification System ..................................................................................... 46

12. Inspections 46
12.1. GMP inspections ................................................................................................... 46
12.2. GCP inspections ................................................................................................... 46
12.3. Pharmacovigilance inspections ............................................................................. 46
12.4. GLP inspections .................................................................................................... 46

13. Innovation Task Force 46
13.1. Minutes of Innovation Task Force ...................................................................... 46
13.2. Innovation Task Force briefing meetings .............................................................. 46
13.4. Nanomedicines activities ...................................................................................... 47

14. Organisational, regulatory and methodological matters 47
14.1. Mandate and organisation of the CHMP ............................................................... 47
14.1.1. Vote by proxy ......................................................................................................... 47
14.1.2. CHMP membership ............................................................................................... 47
14.2. Coordination with EMA Scientific Committees ................................................... 47
14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) ..................................... 47
14.2.2. Paediatric Committee (PDCO) ................................................................................ 47
14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ........ 47
14.3.1. Biologics Working Party (BWP) ............................................................................... 47
14.3.2. Scientific Advice Working Party (SAWP) ................................................................. 48
14.3.3. Ad-hoc Influenza Working Group ........................................................................... 48
14.4. Cooperation within the EU regulatory network .................................................... 48
14.5. Cooperation with International Regulators ........................................................... 48
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee ............................................................................................................. 48
14.7. CHMP work plan .................................................................................................. 49
14.8. Planning and reporting ......................................................................................... 49
14.8.1. Update of the Business Pipeline report for the human scientific committees ................. 49

14.9. Others .................................................................................................................. 49

14.9.1. CHMP Learnings .............................................................................................. 49

15. Any other business 49

15.1. AOB topic ........................................................................................................... 49

List of Participants 50

Explanatory notes 55
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person.

In accordance with the Agency’s policy on handling of declarations of interests of scientific Committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. Robert Porszasz declared an additional competing interest regarding Omecamtiv mecarbil - EMEA/H/C/006112. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. **Adoption of agenda**

CHMP agenda for 18-21 March 2024.

The CHMP adopted the agenda.

1.3. **Adoption of the minutes**

CHMP minutes for 19-22 February 2024 plenary meeting.

The CHMP adopted the minutes for the 19-22 February 2024 plenary.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 11 March 2024.

The CHMP adopted the minutes from the PROM meeting held on 11 March 2024.
2. **Oral Explanations**

2.1. **Pre-authorisation procedure oral explanations**

2.1.1. **Aprocitentan - EMEA/H/C/006080**

treatment of resistant hypertension  
Scope: Oral explanation  
**Action**: Oral explanation to be held on 20 March 2024 at 11:00


The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.2. **Omecamtiv mecarbil - EMEA/H/C/006112**

treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%  
Scope: Oral explanation  
**Action**: Oral explanation to be held on 19 March 2024 at 11:00


The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.3. **Lecanemab - EMEA/H/C/005966**
a disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer’s disease and Mild Alzheimer’s disease (Early Alzheimer’s disease)  
Scope: Oral explanation  
**Action**: Oral explanation to be held on 19 March 2024 at 14:00


The CHMP agreed that an oral explanation was not needed at this time.

See 3.2.

2.2. **Re-examination procedure oral explanations**

No items
2.3. **Post-authorisation procedure oral explanations**

2.3.1. **Rinvoq - upadacitinib - EMEA/H/C/PSUSA/00010823/202302**

AbbVie Deutschland GmbH & Co. KG

**Rapporteur:** Kristina Dunder, **Co-Rapporteur:** Outi Mäki-Ikola, **PRAC Rapporteur:** Petar Mas

**Scope:** Oral explanation

**Action:** Oral explanation to be held on 20 March 2024 at 16:00

The CHMP agreed that an oral explanation was not needed at this time.

See 9.1

2.4. **Referral procedure oral explanations**

No items

3. **Initial applications**

3.1. **Initial applications; Opinions**

3.1.1. **AGILUS - Dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009**

Norgine B.V.; treatment of malignant hyperthermia (including suspected cases)

**Scope:** Opinion

**Action:** For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.2. **Awiqli - Insulin icodec - EMEA/H/C/005978**

Novo Nordisk A/S; treatment of diabetes mellitus in adults

**Scope:** Opinion
Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that insulin icodex is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.3. Dimethyl fumarate Accord - Dimethyl fumarate - EMEA/H/C/006471

Accord Healthcare; for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.4. Dimethyl fumarate Mylan - Dimethyl fumarate - EMEA/H/C/006397

Mylan Ireland Limited; for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.
3.1.5. Dimethyl fumarate Neuraxpharm - Dimethyl fumarate - EMEA/H/C/006500

Neuraxpharm Pharmaceuticals S.L.; for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.6. Emblaveo - Aztreonam / Avibactam - EMEA/H/C/006113

Pfizer Europe Ma EEIG; treatment of complicated Intra-Abdominal Infection (cIAI), complicated Urinary Tract Infection (cUTI), including pyelonephritis, Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), and aerobic Gram-negative infections with limited treatment options

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.7. Fabhalta - Iptacopan - PRIME - Orphan - EMEA/H/C/005764

Novartis Europharm Limited; treatment of paroxysmal nocturnal haemoglobinuria

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been
addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that iptacopan is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendations dated 13 March 2024.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.8. Jubbonti - Denosumab - EMEA/H/C/005964

Sandoz GmbH; treatment of osteoporosis

**Scope:** Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.9. Lytenava - Bevacizumab - EMEA/H/C/005723

Outlook Therapeutics Limited; Treatment of neovascular (wet) age-related macular degeneration (nAMD).

**Scope:** Opinion

**Action:** For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
timetable.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendations dated 11 March 2024.
The summary of opinion was circulated for information.

3.1.10.  **Neoatronic - Dopamine hydrochloride - PUMA - EMEA/H/C/006044**

BrePco Biopharma Limited; Treatment of hypotension in neonates, infants and children

**Scope:** Opinion

**Action:** For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a paediatric use marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendations dated 14 March 2024.
The summary of opinion was circulated for information.

3.1.11.  **Omyclo - Omalizumab - EMEA/H/C/005958**

Celltrion Healthcare Hungary Kft.; treatment of asthma

**Scope:** Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.
3.1.12. **Wyost - Denosumab - EMEA/H/C/006378**

Sandoz GmbH; prevention of skeletal related events with advanced malignancies

**Scope:** Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Jubbonti


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

### 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

#### 3.2.1. **Apadamtase alfa - Orphan - EMEA/H/C/006198**

Takeda Manufacturing Austria AG; treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency

**Scope:** List of outstanding issues

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

#### 3.2.2. **Efanesoctocog alfa - Orphan - EMEA/H/C/005968**

Swedish Orphan Biovitrum AB (publ); Treatment and prophylaxis of bleeding in patients with haemophilia A

**Scope:** List of outstanding issues

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a 2nd list of outstanding issues with a specific timetable.

### 3.2.3. **Fidanacogene elaparvovec - PRIME - ATMP - EMEA/H/C/004774**

indicated for the treatment of severe and moderately severe haemophilia B

**Scope:** List of outstanding issues

**Action:** For information

List of Questions adopted on 08.09.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues. The CHMP was updated on discussions at the CAT.

The Committee endorsed the list of outstanding issues with a specific timetable as adopted by the CAT.

### 3.2.4. **Buprenorphine - EMEA/H/C/006188**

treatment of opioid drug dependence

**Scope:** List of outstanding issues

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

### 3.2.5. **Dabigatran etexilate - EMEA/H/C/006023**

Prevention of venous thromboembolic events

**Scope:** List of outstanding issues

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

### 3.2.6. **Dasatinib - EMEA/H/C/006251**

Indicated for the treatment of chronic myelogenous leukaemia (CML)

**Scope:** List of outstanding issues
Action: For adoption
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. **Dasiglucagon - EMEA/H/C/006214**
treatment of severe hypoglycemia in patients with diabetes
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 09.11.2023.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. **Rituximab - EMEA/H/C/006224**
treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL) and Rheumatoid arthritis
Scope: List of outstanding issues
Action: For adoption
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.9. **Aprocitentan - EMEA/H/C/006080**
treatment of resistant hypertension
Scope: List of outstanding issues
Action: For adoption
See 2.1
The CHMP agreed that an oral explanation was not needed at this time.
The CHMP adopted a 2nd list of outstanding issues with a specific timetable.
3.2.10. Omecamtiv mecarbil - EMEA/H/C/006112

Treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%.

Scope: List of outstanding issues

**Action**: For adoption


The CHMP agreed that an oral explanation was not needed at this time.

See 2.1

The CHMP adopted a 2\textsuperscript{nd} list of outstanding issues with a specific timetable.

3.2.11. Lecanemab - EMEA/H/C/005966

A disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer’s disease and Mild Alzheimer’s disease (Early Alzheimer’s disease).

Scope: List of outstanding issues

**Action**: For adoption


The CHMP agreed that no oral explanation was needed at this time.

The CHMP adopted a 2\textsuperscript{nd} list of outstanding issues with a specific timetable.

3.2.12. rdESAT-6 / rCFP-10 - EMEA/H/C/006177

Diagnosis of infection with Mycobacterium tuberculosis.

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 22.06.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. Ustekinumab - EMEA/H/C/005918

Treatment of adult patients with moderately to severely active Crohn’s disease and active ulcerative colitis.

Scope: List of outstanding issues

**Action**: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the MWP and adopted a list of questions to this expert group.

### 3.2.14. Zolbetuximab - Orphan - EMEA/H/C/005868

Astellas Pharma Europe B.V.; treatment of locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 09.11.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

### 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

#### 3.3.1. Garadacimab - Orphan - EMEA/H/C/006116

CSL Behring GmbH; routine prevention of attacks of hereditary angioedema (HAE)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.2. Aflibercept - EMEA/H/C/006056

treatment of age-related macular degeneration (AMD) and visual impairment

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.3. Beremagene geperpavec - PRIME - Orphan - ATMP - EMEA/H/C/006330

Krystal Biotech Netherlands B.V.; treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Scope: List of questions

Action: For information

The Committee discussed the issues identified in this application. The CHMP was updated on discussions at the CAT.

The Committee endorsed the recommendation and scientific discussion together with the amended list of questions as adopted by the CAT.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. Tiratricol - Orphan - EMEA/H/C/005220

Rare Thyroid Therapeutics International AB; treatment of monocarboxylate transporter 8 (MCT8) deficiency

Scope: Letter by the applicant dated 28.02.2024 requesting an extension to the clock stop to respond to the list of questions adopted in February 2024.

Action: For adoption

List of Questions adopted on 22.02.2024.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in February 2024.

3.4.2. Leniolisib - Orphan - EMEA/H/C/005927

Pharming Technologies B.V.; Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Scope: Letter by the applicant dated 12.03.2024 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in January 2024.

Action: For adoption


The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2024.

3.4.3. Masitinib - Orphan - EMEA/H/C/005897

AB Science; in combination with riluzole for the treatment of adult patients with amyotrophic lateral sclerosis (ALS)
Scope: Letter by the applicant dated 29.02.2024 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in January 2024.

**Action:** For adoption


The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2024.

### 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

### 3.6. Initial applications in the decision-making phase

No items

### 3.7. Withdrawals of initial marketing authorisation application

No items

### 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

#### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

**4.1.1. AMGEVITA - Adalimumab - EMEA/H/C/004212/X/0036/G**

Amgen Europe B.V.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn

Scope: "Extension application to introduce a new strength, 80 mg [0.8 ml (100 mg/ml)] solution for injection, grouped with quality variations

The RMP (version 7.1) is also agreed."

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
4.1.2. COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0199

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Extension application to add a new presentation of Comirnaty Omicron XBB.1.5, 3 micrograms/dose concentrate for dispersion for injection (yellow caps, 3-doses per vial) for infants and children aged 6 months to 4 years."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.3. LUMYKRAS - Sotorasib - EMEA/H/C/005522/X/0009

Amgen Europe B.V.

Rapporteur: Alexandre Moreau

Scope: "Extension application to add a new strength of 240 mg film-coated tablet."

Action: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Reagila - Cariprazine - EMEA/H/C/002770/X/0033

Gedeon Richter Plc.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension application to introduce a new pharmaceutical form (orodispersible tablets). The RMP (version 3.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 09.11.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with
the list of outstanding issues and a specific timetable.

4.2.2. **Spevigo - Spesolimab - EMEA/H/C/005874/X/0006/G**

Boehringer Ingelheim International GmbH

Rapporteur: Kristina Dunder, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Nathalie Gault

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (150 mg) and new route of administration (subcutaneous use), for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age.

This line extension is grouped with a type II variation (C.I.6.a) to extend the indication for Spevigo 450 mg concentrate for solution for infusion to include treatment of generalised pustular psoriasis (GPP) flares in adolescents (from 12 years of age), based on final results from study 1368-0027 (Effisayil 2) and extrapolation; this is a multi-center, randomized, parallel group, double blind, placebo controlled, phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (spesolimab) compared to placebo in preventing GPP flares in patients with history of GPP. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce editorial changes to the PI and update the list of local representatives in the Package Leaflet."

**Action:** For adoption

List of Questions adopted on 09.11.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.3. **XALKORI - Crizotinib - EMEA/H/C/002489/X/0080/G**

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension application to introduce a new pharmaceutical form (granules in capsules for opening) associated with new strengths (20, 50 and 150 mg), grouped with a type II variation (C.I.6.a) to include the treatment of paediatric patients with relapsed or refractory, systemic ALK-positive ALCL or unresectable, recurrent, or refractory ALK-positive IMT to change the lower end of the age range from ≥6 years to ≥1 year for Xalkori following the assessment of II/0072 based on final results from study ADVL0912. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted."

**Action:** For adoption


The Committee discussed the issues identified in this application, relating to quality and
clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.3. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question**

No items

4.4. **Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008**

4.4.1. **Eurartesim - Piperaquine tetrathosphate / Artenimol - EMEA/H/C/001199/X/0041**

Alfasigma S.p.A.

Rapporteur: Janet Koenig

Scope: Letter by the applicant dated 23.02.2024 requesting an extension to the clock stop to respond to the list of questions adopted in January 2024.

**Action:** For adoption

List of Questions adopted on 25.01.2024.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in January 2024.

4.4.2. **Opsumit - Macitentan - EMEA/H/C/002697/X/0051/G**

Janssen-Cilag International N.V.

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Patrick Vrijlandt, PRAC

Rapporteur: Maria del Pilar Rayon

Scope: Change of timetable to respond to the list of questions adopted in February 2024.

**Action:** For information

List of Questions adopted on 22.02.2024.

The CHMP noted the change in timetable.

4.5. **Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008**

No items
5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Alecensa - Alectinib - EMEA/H/C/004164/II/0047

Roche Registration GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova

Scope: "Extension of indication to include the use of Alecensa as monotherapy in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) as adjuvant treatment following tumour resection, based on final results from study BO40336 (ALINA), a randomized, active controlled, multicenter, open-label, Phase III study designed to evaluate the efficacy and safety of alectinib compared with platinum-based chemotherapy in the adjuvant setting in patients with completely resected Stage IB (tumors 4 cm) to Stage IIIA ALKpositive NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection.". Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.2. Bimzelx - Bimekizumab - EMEA/H/C/005316/II/0020

UCB Pharma S.A.

Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Martirosyan

Scope: "Extension of indication to include treatment of moderate to severe hidradenitis suppurativa (HS) in adults, based on final results from study HS0003 (BE HEARD I) and study HS0004 (BE HEARD II). These are phase 3, randomized, double blind, placebo controlled, multicenter, pivotal studies evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe HS. Further supportive data are based on the results of phase 2 study HS0001 and phase 3 currently ongoing open-label extension study HS0005. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.10 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.3."
Action: For adoption

Request for Supplementary Information adopted on 25.01.2024, 12.10.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendations dated 20 March 2024.

The summary of opinion was circulated for information.

5.1.3. CellCept - Mycophenolate mofetil - EMEA/H/C/000082/II/0170/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher

Scope: “C.I.6.a: Extension of indication to include paediatric patients (3 months to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 3 months, based on pharmacokinetic data, published literature and the Roche Global Safety Database. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly.

Type IB (C.I.2): To update section 4.2 of the SmPC for the CellCept 500 mg tablets formulation in order to be in line with the other three CellCept formulations; and for alignment with the current QRD guidance, the Package Leaflet was updated to cross reference section 2 in section 6 for sodium content.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring the PI in line with the latest QRD template version 10.3.”

Action: For adoption


The Committee discussed the issues identified in this application relating to the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.4. Dupixent - Dupilumab - EMEA/H/C/004390/II/0081

Sanofi Winthrop Industrie

Rapporteur: Jan Mueller-Berghaus

Scope: “Extension of indication to include treatment of children aged 1 year and older to the already approved eosinophilic esophagitis (EoE) indication for Dupixent based on final results from study R668-EE-1877 (Part A, Part B, and Part A Addendum) - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.
The Committee adopted a request for supplementary information with a specific timetable.

5.1.5. Fasenra - Benralizumab - EMEA/H/C/004433/II/0052

AstraZeneca AB

Rapporteur: Fátima Ventura (PT) (MNAT with EL for Clinical Pharmacology, EL for Clinical Efficacy, EL for Clinical Safety), PRAC Rapporteur: David Olsen

Scope: “Extension of indication to include treatment of eosinophilic granulomatosis with polyangiitis for Fasenra, based on results from study D3253C00001 (Mandara); this was a randomised, double-blind, multicentre, parallel group, active-controlled, non-inferiority study that evaluated the efficacy and safety of benralizumab compared with mepolizumab in treatment of patients with EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.1 of the RMP has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes. As part of the application, the MAH is requesting a 1-year extension of the market protection.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical efficacy and the request for 1 year or market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. IMCIVREE - Setmelanotide - Orphan - EMEA/H/C/005089/II/0018

Rhythm Pharmaceuticals Netherlands B.V.

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Anna Mareková

Scope: "Extension of indication to include the population of children aged 2 years and above for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin Type 1 (PCSK1) deficiency or biallelic leptin receptor (LEPR) deficiency and Bardet-Biedl Syndrome (BBS) for IMCIVREE, based on the final results from study RM-493-033 "A Phase 3 Multicenter, One-Year, Open-Label Study of Setmelanotide in Pediatric Patients Aged 2 To <6 Years of Age with Rare Genetic Causes of Obesity"; this is an open label study to evaluate the weight-related parameters along with the safety and tolerability of setmelanotide in patients aged 2 to <6 years. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes to the PI."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical, quality, safety and RMP aspects.

The Committee adopted a request for supplementary information with a specific timetable.
5.1.7. Imfinzi - Durvalumab - EMEA/H/C/004771/II/0064

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Carolina Prieto Fernandez, PRAC
Rapporteur: David Olsen

Scope: "Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements for IMFINZI, based on the interim results from study D9106C00001 (AEGEAN); this is a Phase III, double-blind, placebo-controlled, multi-center international study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application related to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Kevzara - Sarilumab - EMEA/H/C/004254/II/0044

Sanofi Winthrop Industrie

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Monica Martinez Redondo

Scope: "Extension of indication to include treatment of Polymyalgia Rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper for Kevzara, based on results from study EFC15160; this is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica; As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP is also submitted. As part of the application, the MAH is requesting a 1-year extension of the market protection."

Action: For adoption

The Committee discussed the issues identified in this application related to clinical aspects and the request for one year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. Kisqali - Ribociclib - EMEA/H/C/004213/II/0045

Novartis Europharm Limited

Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Stage II or Stage III early breast cancer, irrespective of nodal status, in combination with an AI for Kisqali based on study CLEE011012301C (NATALEE); This is a
global, Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with ET versus ET alone as adjuvant treatment in patients with HR-positive, HER2-negative, early breast cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

**Action**: For adoption


The Committee discussed the issues identified in this application related to multidisciplinary, benefit-risk and clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.10. **Nilemdo - Bempedoic acid - EMEA/H/C/004958/II/0031**

Daiichi Sankyo Europe GmbH

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Kimmo Jaakkola

Scope: “Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk, based on results from study 1002-043 (CLEAR). CLEAR Outcomes Study is a phase 3 multi-centre randomised, double-blind, placebo-controlled study to evaluate whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 4.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor formatting changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 22.02.2024, 09.11.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (29 positive votes out of 31 votes) together with the CHMP Assessment Report and translation timetable.

The divergent position (Maria Concepcion Prieto Yerro, Sol Ruiz) was appended to the opinion.

The summary of opinion was circulated for information.

5.1.11. **Nustendi - Bempedoic acid / Ezetimibe - EMEA/H/C/004959/II/0035**

Daiichi Sankyo Europe GmbH

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Kimmo Jaakkola
Scope: “Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk for NUSTENDI, based on results from Study 1002-043, known as the CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen] Outcomes Trial; this is a Phase 3, randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant; As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 22.02.2024, 09.11.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (29 positive votes out of 31 votes) together with the CHMP Assessment Report and translation timetable.

The divergent position (Maria Concepcion Prieto Yerro, Sol Ruiz) was appended to the opinion.

The summary of opinion was circulated for information.

5.1.12. **Onivyde pegylated liposomal - Irinotecan hydrochloride trihydrate - Orphan - EMEA/H/C/004125/II/0034**

Les Laboratoires Servier

Rapporteur: Filip Josephson, PRAC Rapporteur: David Olsen

Scope: “Extension of indication to include first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas for Onivyde in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) based on final results from phase 3 study NAPOLI 3 (D-US-60010-001); this is an interventional study with a primary objective to evaluate the efficacy of the regimen of irinotecan liposome injection + oxaliplatin + 5-fluorouracil (5-FU)/leucovorin (LV) versus nab-paclitaxel + gemcitabine in improving overall survival (OS) in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. The updated RMP version 4.1 is also submitted.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.
5.1.13. Otezla - Apremilast - EMEA/H/C/003746/II/0044/G

Amgen Europe B.V.

Rapporteur: Finbarr Leacy, PRAC Rapporteur: Monica Martinez Redondo

Scope: "A grouped application of a Type II Variation with two Type IA Variations, as follows: Type II (C.I.6.a): Extension of indication to include the treatment of moderate to severe chronic plaque psoriasis in children and adolescents from the age of 6 years who have a contraindication, have an inadequate response, or are intolerant to at least one other systemic therapy or phototherapy for OTEZLA, based on final results from study CC-10004-PPSO-003 as well as results from studies CC-10004-PPSO-001 and CC-10004-PPSO-004. CC-10004-PPSO-003 is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of apremilast (CC-10004) in paediatric subjects from 6 through 17 years of age with moderate to severe plaque psoriasis. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 15.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial and formatting changes to the PI and to update the list of local representatives in the Package Leaflet.

2 Type IA (B.II.e.5.a.1): Update of sections 6.5 and 8 of the SmPC to introduce two new pack sizes within approved range as a result of the indication update (27 film-coated tablets (4 x 10 mg, 23 x 20 mg) and 14 film-coated tablets (14 x 20 mg), in a pack size of 56 tablets)."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.14. Pravafenix - Fenofibrate / Pravastatin sodium - EMEA/H/C/001243/II/0037

Laboratoires SMB s.a.

Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault

Scope: "Extension of indication to include treatment of mixed hyperlipidaemia in adult patients while on a treatment with pravastatin 40 mg monotherapy or on another moderate-intensity statin regimen for PRAVAFENIX, based on final results from the non-interventional PASS: POSE (Pravafenix Observational Study in Europe); this is a European, observational, three-year cohort comparative study on the safety of the fixed dose combination pravastatin 40 mg/fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice. As a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to ERA and RMP aspects.

The Committee adopted a request for supplementary information with a specific timetable.
5.1.15. Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0022

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Bianca Mulder

Scope: “Extension of indication for RETSEVMO to include the treatment of adults with advanced or metastatic RET fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

Action: For adoption

Request for Supplementary Information adopted on 25.01.2024, 09.11.2023, 20.07.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (28 positive out of 30 votes) together with the CHMP Assessment Report and translation timetable.

The divergent position (Peter Mol, Paolo Gasparini) was appended to the opinion.

The CHMP noted the letter of recommendations dated 19 March 2024.

The summary of opinion was circulated for information.

5.1.16. RYBREVANT - Amivantamab - EMEA/H/C/005454/II/0011

Janssen-Cilag International N.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Gabriele Maurer

Scope: “Extension of indication to include amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including a third-generation EGFR tyrosine kinase inhibitor (TKI) for RYBREVANT, based on the final results from study 61186372NSC3002 (MARIPOSA 2); this is a randomized, open label, multicenter Phase 3 study that compares efficacy and safety of amivantamab in combination with carboplatin and pemetrexed (ACP) with carboplatin and pemetrexed (CP). The primary objective of the MARIPOSA 2 study is to compare efficacy, as demonstrated by PFS, in participants treated with ACP versus CP alone. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2, 6.6 and 9 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the EU RMP has also been submitted. In addition, the marketing authorisation holder (MAH) is requesting an additional year of market protection.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
**Action:** For adoption

The Committee discussed the issues identified in this application relating to the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.17. Slenyto - Melatonin - EMEA/H/C/004425/II/0025

RAD Neurim Pharmaceuticals EEC SARL

Rapporteur: Kristina Dunder, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include treatment of neurogenetic disorders (e.g., Angelman syndrome, Rett syndrome, Tuberous sclerosis complex and Williams syndrome) for SLENYTO, based on Phase III study NEU_CH_7911, post-marketing data and literature; As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and to the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.18. Triumeq - Dolutegravir / Abacavir / Lamivudine - EMEA/H/C/002754/II/0116

ViiV Healthcare B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg for Triumeq Dispersible Tablets, based on PK, safety, and efficacy data observed in the final results of study 205860 (IMPAACT 2019), further supported by extrapolation to data generated in adults and additional data in paediatric patients with the single entities. IMPAACT 2019 is a Phase 1/2 open-label, multicenter, multiple dose study of dolutegravir/lamivudine/abacavir fixed dose combination tablets in treatment-experienced and treatment-naive HIV-1-infected children less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI."

**Action:** For adoption

Request for Supplementary Information adopted on 25.01.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.
5.1.19. Vabysmo - Faricimab - EMEA/H/C/005642/II/0005

Roche Registration GmbH

Rapporteur: Jayne Crowe, PRAC Rapporteur: Carla Torre

Scope: “Extension of indication to include treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) for Vabysmo, based on results from the two phase 3 studies: GR41984 (BALATON) in patients with branch retinal vein occlusion (BRVO) and GR41986 (COMINO) in patients with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO). These are global, multicenter, randomized, double-masked, active comparator-controlled, parallel-group, 2-part studies evaluating the efficacy, safety and PK of faricimab. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI.”

Action: For adoption

Request for Supplementary Information adopted on 09.11.2023.

The Committee discussed the issues identified in this application relating to efficacy, clinical and safety aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.20. Valdoxan - Agomelatine - EMEA/H/C/000915/II/0051

Les Laboratoires Servier

Rapporteur: Eva Skovlund, PRAC Rapporteur: Pernille Harg

Scope: “Extension of indication to include new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depressive episodes, if depression is unresponsive to psychological therapy alone, for Valdoxan, further to the results of the phase 2 (CL2-20098-075) and phase 3 (CL3-20098-076) paediatric clinical studies included in the Paediatric Investigation Plan number EMEA-001181-PIP-11; As a consequence, the sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. The updated RMP version 25.1 has also been submitted.”

Action: For adoption


The Committee discussed the issues identified in this application relating to the product information.

The Committee adopted a 4th request for supplementary information with a specific timetable.

5.1.21. Veklury - Remdesivir - EMEA/H/C/005622/II/0053/G

Gilead Sciences Ireland UC
Rapporteur: Janet Koenig (DE) (MNAT with AT for Quality), PRAC Rapporteur: Eva Jirsová

Scope: “Grouped application comprising two extensions of indication to include treatment of paediatric patients weighing at least 1.5 kg for VEKLURY, based on final results from study GS-US-540-5823; this is a Phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of remdesivir in participants from birth to < 18 years of age with COVID-19. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted.”

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted a request for supplementary information with a specific timetable.

5.1.22. Xtandi - Enzalutamide - EMEA/H/C/002639/II/0063

Astellas Pharma Europe B.V.

Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Maria del Pilar Rayon

Scope: “Extension of indication to include treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy, for Xtandi, based on final results from study MDV3100-13 (EMBARK); this is a phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy, and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendations dated 19 March 2024.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items
5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. In vitro diagnostic medical device - EMEA/H/D/006470

to detect amplification of the HER2/neu gene via quantitative fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer and adenocarcinomas of the stomach (including gastroesophageal junction) tissue specimens

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a list of questions with a specific timetable.

6.3.2. In vitro diagnostic medical device - EMEA/H/D/006454

To detect PD-L1 protein

Scope: Opinion

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.4. Companion diagnostics – follow-up consultation

No items
7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. sargramostim - H0006411

To increase survival in adult and paediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

The CHMP adopted the recommendations for PRIME eligibility.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website, in the PRIME homepage, under Outcome of eligibility section.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0109

Takeda Pharma A/S

Rapporteur: Peter Mol, PRAC Rapporteur: Bianca Mulder

Scope: "Extension of indication to include in combination with cyclophosphamide,"
doxorubicin, and prednisone (CHP) treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) for Adcetris based on the final overall survival results of Echelon-2 (SGN035-014), A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 19.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”

Withdrawal of extension of indication application. The SAG minutes are tabled for information.

**Action:** For information

The CHMP noted the withdrawal of the extension of indication application.

### 9.1.2. Cuprymina – copper (64Cu) chloride – EMEA/H/C/002136

A.C.O.M. - Advanced Center Oncology Macerata; radiopharmaceutical (radiolabelling of carrier molecules)

Rapporteur: Paolo Gasparini, Co-Rapporteur: Janet Koenig

**Scope:** Withdrawal of marketing authorisation

**Action:** For information

The CHMP noted the withdrawal of marketing authorisation.

### 9.1.3. Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0072, Orphan, ATMP

Novartis Europharm Limited

Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

**Scope:** quality

Withdrawal of Type II variation application

**Action:** For information

Request for Supplementary Information adopted on 08.09.2023.

The CHMP noted the withdrawal of the type II variation application.

### 9.1.4. Ondexxya - Andexanet alfa - EMEA/H/C/004108/II/0044

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

**Scope:** "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information based on the final results from study 18-513 (ANNEXA-I), listed as a specific obligation in the Annex II; this is a phase 4 randomised controlled trial to investigate the efficacy and safety of andexanet alfa versus usual care in patients with acute intracranial haemorrhage taking apixaban, rivaroxaban or edoxaban. Consequently,"
the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation. The Annex II and Package Leaflet are updated accordingly. The updated RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the latest QRD template version 10.3.”

**Action**: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

### 9.1.5. Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0028

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Bianca Mulder

**Scope**: "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study LIBRETTO-431 (JZJC) listed as a specific obligation in the Annex II (SOB/002); this is a randomized Phase 3 study comparing selpercatinib to platinum-based and pemetrexed therapy with or without pembrolizumab in patients with locally advanced or metastatic, RET-fusion-positive NSCLC. The Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. In addition, the MAH took the opportunity to update Annex II.”

**Action**: For information

Request for Supplementary Information adopted on 07.03.2024.

The CHMP noted the request for supplementary information adopted on 7 March 2024.

### 9.1.6. Rinvoq - upadacitinib - EMEA/H/C/PSUSA/00010823/202302

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Petar Mas

**Scope**: PRAC recommendation on PSUSA

**Action**: For adoption

See 2.3

The CHMP was updated on discussions at the PRAC.

The CHMP agreed that an oral explanation was not needed at this time.

The CHMP adopted the PRAC recommendation on the PSUSA by consensus.

### 9.1.7. WS2552

**Ongentys - Opicapone - EMEA/H/C/002790/WS2552/0060**

**Ontilyv - Opicapone - EMEA/H/C/005782/WS2552/0015**

Bial Portela & Companhia S.A.

Lead Rapporteur: Martina Weise, PRAC Rapporteur: Maria del Pilar Rayon

**Scope**: "Extension of indication to include treatment of signs and symptoms of Parkinson’s..."
Disease for Ongentys/Ontilyv, based on final results from study BIA-91067-303; this is a pivotal Phase III, multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of opicapone in patients with early idiopathic Parkinson’s Disease receiving treatment with L-DOPA plus a DDCI, and who are without signs of any motor complication. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted (only applicable to Ongentys) to reflect the changes made upon approval of the informed consent application, to keep consistency between the eCTD lifecycles of the two marketing authorisations (Ongentys and Ontilyv). Furthermore, the PI is brought in line with the latest QRD template version 10.3. In addition, as part of the application the MAH is requesting a 1-year extension of the market protection. “Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).

Withdrawal of extension of indication application

**Action:** For information

Request for Supplementary Information adopted on 09.11.2023.

The CHMP noted the withdrawal of extension of indication application.

### 9.1.8. Remsima - Infliximab - EMEA/H/C/002576/II/0133/G

Celltrion Healthcare Hungary Kft.

Rapporteur: Outi Mäki-Ikola

Scope: “Grouped application comprising three type II variations (C.I.4) as follows:
- Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (crohn’s disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease.
- Update of sections 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (> 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study). The RMP version 16.1 has also been submitted. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI.”

**Action:** For discussion

Request for Supplementary Information adopted on 09.11.2023.
The Committee discussed the issues identified in this application.
The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.9. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675

AstraZeneca AB; prevention of COVID-19
Rapporteur: Sol Ruiz
Scope: Withdrawal of marketing authorisation
Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

10. Referral procedures


10.1.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065

Orexigen Therapeutics Ireland Limited
Referral Rapporteur: Thalia Marie Estrup Blicher, Referral Co-Rapporteur: Daniela Philadelphy
Scope: Revised timetable
Action: For adoption

The CHMP adopted a revised timetable.
Submission of responses: 13.03.2024
Re-start of the procedure: 28.03.2024
Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 04.04.2024
Comments: 11.04.2024
Scientific Advisory Group meeting: 12.04.2024
Updated rapporteur/co-rapporteur joint assessment report circulated to CHMP: 17.04.2024
CHMP LoOI or CHMP opinion: April 2024 CHMP

10.1.2. Ocaliva - obeticholic acid - EMEA/H/A-20/1531

Advanz Pharma Limited
Referral Rapporteur: Carolina Prieto Fernandez, Referral Co-Rapporteur: Paolo Gasparini
Scope: Revised timetable

**Action:** For adoption


The CHMP adopted a revised timetable.

Submission of responses: 07.03.2024

Re-start of the procedure: 28.03.2024

Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 04.04.2024

Ad-hoc expert group meeting (AHEG): 10.04.2024

Comments: 11.04.2024

Updated rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 17.04.2024

CHMP list of outstanding issues or CHMP opinion: April 2024 CHMP

### 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

#### 10.2.1. Colistimethate sodium (CMS) – EMEA/H/A-5(3)/1524

Various MAHs

Referral Rapporteur: Martina Weise, Referral Co-Rapporteur: Ewa Balkowiec Iskra

Scope: List of outstanding issues

**Action:** For adoption

Review of the ratio of polymyxins E1 and E2 in colistin starting material and of the (sulfomethylation) composition profile of CMS finished product.


The CHMP adopted a 2nd list of outstanding issues together with the timetable.

CHMP list of outstanding issues: 21.03.2024

Submission of responses part 1/2: 31.03.2025


CHMP discussion: April 2025 CHMP

Submission of responses part 2/2: 02.04.2026

Re-start of the procedure: 23.04.2026

Rapporteurs’ joint assessment report circulated to CHMP: 02.07.2026.

Comments: 09.07.2026
Updated Rapporteurs’ joint assessment report circulated to CHMP: 15.07.2026.

CHMP list of outstanding issues/CHMP opinion: July 2026 CHMP

10.3. **Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004**

No items

10.4. **Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

10.4.1. **Micrazym – porcine pancreas enzymes - EMEA/H/A-29(4)/1535**

Avva Pharmaceuticals Ltd.

Referral Rapporteur: Patrick Vrijlandt, Referral Co-Rapporteur: Martina Weise

Scope: opinion

**Action:** For adoption

Decentralised Procedure number: NL/H/5258/001-002/DC, notification sent by the Agency of The Netherlands dated 21 December 2023 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

List of questions adopted on 25.01.2024.

The CHMP adopted an opinion by majority (25 positive out of 31 votes), concluding that the benefits of Micrazym outweigh its risks, and the marketing authorisation should be granted in the Netherlands and in the Member States of the EU where the company has applied for a marketing authorisation: Austria, Belgium, Cyprus, Czechia, Denmark, Finland, Germany, Ireland, Luxembourg, Norway, Slovakia, Spain and Sweden.

The divergent opinion (John Joseph Borg, Jan Mueller-Berghaus, Helena Panayiotopoulou, Maria Concepcion Prieto Yerro, Sol Ruiz, Martina Weise) was appended to the opinion.

The questions-and-answer document was circulated for information.

10.5. **Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

10.5.1. **Havrix – Hepatitis A virus (inactivated, adsorbed) - EMEA/H/A-30/1527**

GlaxoSmithKline Biologicals

Referral Rapporteur: Maria Grazia Evandri, Referral Co-Rapporteur: Lyubina Racheva

Scope: List of outstanding issues

**Action:** For adoption

Harmonisation exercise for Havrix and associated names. Product Information
harmonisation was triggered by the MAH.

List of questions adopted on 09.11.2023.

The CHMP adopted a list of outstanding issues with a timetable:

CHMP list of outstanding issues: March 2024 CHMP
Submission of responses: 08.05.2024
Re-start of the procedure: 30.05.2024
Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 06.06.2024
Comments: 13.06.2024
Updated Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 19.06.2024
CHMP LoOI or CHMP opinion: June 2024 CHMP


No items


10.7.1. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529

Various MAHs

Re-examination Referral Rapporteur: Tomas Radimersky, Re-examination Referral Co-Rapporteur: Alar Irs

Scope: Opinion

**Action:** For adoption

Article 31 procedure triggered by the Agency of Medicines and Medical Devices (AEMPS) in Spain, concerning the contract research organisation (CRO) Synapse Labs Pvt. Ltd., located in Kharadi, Pune, India.

The CHMP adopted an opinion by consensus, re-confirming the recommendation to suspend medicines for which adequate bioequivalence data are lacking. To lift the suspension, companies must provide alternative data demonstrating bioequivalence. In Member States where the medicinal product is considered critical, the suspension can be deferred for up to 24 months. Medicines for which ongoing marketing authorisation applications rely solely on data from Synapse Labs will not be granted authorisation in the EU.

For some medicinal products the CHMP concluded that there was alternative data to establish bioequivalence vis-à-vis the EU reference medicinal product and recommended the maintenance of these marketing authorisations.
Bioequivalence vis-à-vis the EU reference medicinal product has been established for a marketing authorisation application.

An updated list of the medicines affected by the procedure is available on EMA’s website.

The CHMP adopted the assessment report.

The public health communication was circulated for information.


No items

10.9. Disagreement between Member States on Type II variation–Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items


No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation–Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

10.11.1. Lorazepam Macure – lorazepam - EMEA/H/A-13/1536

Macure Pharma ApS

Referral Rapporteur: Peter Mol, Referral Co-Rapporteur: Kristina Dunder

Scope: List of questions

Action: For adoption

Variation number in decentralised procedure: NL/H/4353/001/II/004, notification sent by the Agency of The Netherlands dated 01 February 2024 notifying of the start of a referral under Article 13(1) of Regulation No 1234/2008.

The CHMP adopted a list of questions with a timetable:

CHMP list of questions: March 2024 CHMP

Submission of responses: 09.05.2024

Re-start of the procedure: 30.05.2024

Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 06.06.2024

Comments: 13.06.2024

Updated Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 19 June 2024
11. Pharmacovigilance issue

11.1. Early Notification System

March 2024 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action**: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items
No items

13.4. **Nanomedicines activities**
No items

### 14. Organisational, regulatory and methodological matters

#### 14.1. Mandate and organisation of the CHMP

14.1.1. **Vote by proxy**

The Romanian member Simona Badoi gave a proxy to Bruno Sepodes for the whole meeting.

14.1.2. **CHMP membership**

No items

#### 14.2. Coordination with EMA Scientific Committees

14.2.1. **Pharmacovigilance Risk Assessment Committee (PRAC)**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for March 2024

**Action:** For adoption

The CHMP adopted the EURD list.

14.2.2. **Paediatric Committee (PDCO)**

Agenda of the March 2024 PDCO plenary meeting.

**Action:** For information

The CHMP noted the PDCO agenda.

#### 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. **Biologics Working Party (BWP)**

Chair: Sean Barry, Vice-Chair: Francesca Luciani
Reports from BWP March 2024 meeting to CHMP for adoption:
- 12 reports on products in scientific advice and protocol assistance
- 16 reports on products in pre-authorisation procedures
- 1 report on products in post-authorisation procedures

**Action:** For adoption
The CHMP adopted the BWP reports.

### 14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 04-07 March 2024. Table of conclusions

**Action:** For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

### 14.3.3. Ad-hoc Influenza Working Group

Scope: EU Strain selection for the Influenza Vaccines for the Season 2024/2025: Report from the Ad Hoc Influenza working group to the BWP

**Action:** For adoption

The CHMP adopted the report from the Ad Hoc Influenza working group.

Scope: EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2024/2025

**Action:** For adoption

The CHMP adopted the EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2024/2025.

### 14.4. Cooperation within the EU regulatory network

No items

### 14.5. Cooperation with International Regulators

No items

### 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items
14.7. **CHMP work plan**

No items

14.8. **Planning and reporting**

14.8.1. **Update of the Business Pipeline report for the human scientific committees**

Q1-2024 initial marketing authorisation application submissions with eligibility request to central procedure

**Action:** For information

The CHMP noted the information.

14.9. **Others**

14.9.1. **CHMP Learnings**

CHMP: Outi Mäki-Ikola

Collection, discussion and recording of CHMP learnings.

**Action:** For information

The CHMP noted the information.

15. **Any other business**

15.1. **AOB topic**

No items
### List of Participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 18-21 March 2024 CHMP meeting, which was held in-person.

An asterisk (*) after the role, in the second column, signals that the member/alternate attended remotely. Additional experts participated in (part of) the meeting, either in person or remotely.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harald Enzmann</td>
<td>Chair</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Daniela Philadelphia</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christian Gartner</td>
<td>Alternate</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christophe Focke</td>
<td>Member</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Karin Janssen van Doorn</td>
<td>Alternate</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lyubina Racheva Todorova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Gergana Lazarova</td>
<td>Alternate</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margaretta Bego</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Selma Arapovic Dzakula</td>
<td>Alternate</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Helena Panayiotopoulou</td>
<td>Member</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tomas Radimersky</td>
<td>Member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petr Vrbata</td>
<td>Alternate</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Thalia Marie Estrup Blicher</td>
<td>Member</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Aaron Sosa Mejia</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No participation in final deliberations and voting on:</td>
<td>Awiqli - Insulin icodex - EMEA/H/C/005978</td>
</tr>
<tr>
<td>Alar Irs</td>
<td>Member</td>
<td>Estonia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Edward Laane</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Outi Mäki-Ikola</td>
<td>Member</td>
<td>Finland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Johanna Lähteenvuo</td>
<td>Alternate</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alexandre Moreau</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Martina Weise</td>
<td>Member</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Janet Koenig</td>
<td>Alternate</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Konstantina Alexopoulo</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anastasia Mountaki</td>
<td>Alternate</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------</td>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------</td>
</tr>
<tr>
<td>Robert Porszasz</td>
<td>Member</td>
<td>Hungary</td>
<td>No participation in discussion, final deliberations and voting on:</td>
<td>Omecamtiv mecarbil - EMEA/H/C/006112</td>
</tr>
<tr>
<td>Beata Maria Jakline Ullrich</td>
<td>Alternate*</td>
<td>Hungary</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hrefnag Gudmundsdottir</td>
<td>Member</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hjalti Kristinsson</td>
<td>Alternate</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jayne Crowe</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Finbarr Leacy</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Paolo Gasparini</td>
<td>Member</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Grazia Evandi</td>
<td>Alternate</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Elita Poplav ska</td>
<td>Member</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Vilma Petrikaite</td>
<td>Member</td>
<td>Lithuania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Larisa Gorobets</td>
<td>Alternate*</td>
<td>Lithuania</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Martine Trauffler</td>
<td>Member</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td>Dupixent - Dupilumab EMEA/H/C/004390/II/0081</td>
</tr>
<tr>
<td>Alexandra Branchu</td>
<td>Alternate</td>
<td>Luxembourg</td>
<td>No participation in discussion, final deliberations and voting on:</td>
<td>Kevzara - Sarilumab EMEA/H/C/004254/II/0044</td>
</tr>
<tr>
<td>John Joseph Borg</td>
<td>Member</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Peter Mol</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Patrick Vrijlandt</td>
<td>Alternate</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ingrid Wang</td>
<td>Member</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Eva Skovlund</td>
<td>Alternate</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ewa Balkowiec Iska</td>
<td>Member</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Grzegorz Cessak</td>
<td>Alternate</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bruno Sepodes</td>
<td>Member (Vice-Chair)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Fátima Ventura</td>
<td>Alternate</td>
<td>Portugal</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Dana Gabriela Marin</td>
<td>Alternate</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Frantisek Drafi</td>
<td>Member</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jana Klimasová</td>
<td>Alternate*</td>
<td>Slovakia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Andreja Kranjc</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Concepcion Prieto Yerro</td>
<td>Member</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carolina Prieto Fernandez</td>
<td>Alternate</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristina Dunder</td>
<td>Member</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Filip Josephson</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bruno Delafont</td>
<td>Co-opted member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carla Torre</td>
<td>Co-opted member</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Co-opted member</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Blanka Hirschlerova</td>
<td>Co-opted member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Co-opted member</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Adarsh Sylar Kumar</td>
<td>Expert</td>
<td>Ireland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Sabine Mayrhofer</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Thadeus Bao Quan Nguyen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Antonio Gomez Outes</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johanna de Groot</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Susan Uiterwaal</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jana Schweigertová</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marcin Kolakowski</td>
<td>Expert</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anna Zadrożna</td>
<td>Expert</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pawel Pawłowski</td>
<td>Expert</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Dominik Langer</td>
<td>Expert</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Koenraad Brusselmans</td>
<td>Expert</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Anissa Benlazar</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Céline Jumeau</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pierre Demolis</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Clemens Mittmann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carin Bergquist</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Macarena Gajardo Alvarez</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Elmer Schabel</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rosália Ruano</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Camps</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Violaine Closson Carella</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nathalie Dumarcet</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lidija Prka</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Danica Juričić Nahal</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ivona Jukić</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tomás Arroyo Pérez</td>
<td>Expert</td>
<td>Spain</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Lenka Králová</td>
<td>Expert</td>
<td>Czech Republic</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tereza Bažantová</td>
<td>Expert</td>
<td>Czech Republic</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ingrid Lund</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Benita Cullen</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Brian Aylward</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Catherine Byrne</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Joseph De Courcey</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------</td>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Olive Smyth</td>
<td>Expert</td>
<td>Ireland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Rosemary Heneghan</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Emma Fagan</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Paale-Hyvärinen</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Stefan Bonné</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Milica Mitrevski</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angelo Molinaro</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mette Linnert Jensen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ebru Gulsun Karakoc Madsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Adrian Post</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Friederike Marei Feldmann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Franziska Wolter</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Georgios Aislaitner</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marion Haberkamp</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ellen Pantke</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Uwe Lipke</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Juliane Rau</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johanna Kuhlmann-Gottke</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Julia Katharina Maier</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Karen Götz</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hilke Zander</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Susanne Müller-Egert</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jens-Peter Hartmann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Robert Pollmann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sara Tognarelli</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Jörg Engelbergs</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christian Baarlink</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sandrine Chiappini</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Valeria Zoccano</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Brigitte Müller</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petar Mas</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Panagiota Tsantili</td>
<td>Expert</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>María Jesús Lamas Díaz</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ilona G. Reischl</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katarzyna Postek-Kaczmarczyk</td>
<td>Expert</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angela Garau</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marco van Teijlingen</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katalina Mettke</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------</td>
<td>----------------------</td>
<td>--------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Eduardo Olivas Encarnación</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ines Almendros López</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan Welink</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Yseult Brun</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anis Nouichi</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alfredo Garcia Arieta</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>

A representative from the European Commission attended the meeting.

Observers from Health Canada (Canada), MHLW/PMDA (Japan) and Swissmedic (Switzerland) attended the meeting.

Meeting run with the help of EMA staff.

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.
Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

**Oral explanations (section 2)**

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to ongoing applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

**Initial applications (section 3)**

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.
Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.
Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP’s Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group’s main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/
Annex to 18-21 March 2024 CHMP Minutes
Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES ................................................................. 3
A.1. ELIGIBILITY REQUESTS.............................................................. 3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications ............... 3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION ............................ 3

B. POST-AUTHORISATION PROCEDURES OUTCOMES .................. 3
B.1. Annual re-assessment outcomes ..................................................... 3
B.1.1. Annual reassessment for products authorised under exceptional circumstances .... 3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES .......... 3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal .......... 3
B.2.2. Renewals of Marketing Authorisations for unlimited validity ............. 3
B.2.3. Renewals of Conditional Marketing Authorisations ............................ 4
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES .......... 5
B.4. EPARs / WPARs ........................................................................ 8
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES .......... 10
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects ............... 10
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .......... 16
B.5.3. CHMP-PRAC assessed procedures ............................................. 33
B.5.4. PRAC assessed procedures ....................................................... 44
B.5.5. CHMP-CAT assessed procedures .............................................. 47
B.5.6. CHMP-PRAC-CAT assessed procedures ..................................... 47
B.5.7. PRAC assessed ATMP procedures ............................................. 47
B.5.8. Unclassified procedures and worksharing procedures of type I variations .... 47
B.5.9. Information on withdrawn type II variation / WS procedure .................. 48
B.5.10. Information on type II variation / WS procedure with revised timetable .... 49
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION ........ 49
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information .................................................. 50
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information...................................................................................................................... 51
B.6.4. Annual Re-assessments: timetables for adoption .......................................................... 54
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed ........................................................................... 55
B.6.6. VARIATIONS – START OF THE PROCEDURE.......................................................... 55
B.6.7. Type II Variations scope of the Variations: Extension of indication ....................... 55
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects ................................. 60
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .............. 63
B.6.10. CHMP-PRAC assessed procedures .................................................................. 70
B.6.11. PRAC assessed procedures ............................................................................ 72
B.6.12. CHMP-CAT assessed procedures .................................................................. 76
B.6.13. CHMP-PRAC-CAT assessed procedures ............................................................. 76
B.6.14. PRAC assessed ATMP procedures ..................................................................... 77
B.6.15. Unclassified procedures and worksharing procedures of type I variations ....... 77
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY ........................................ 79
B.7.1. Yearly Line listing for Type I and II variations .................................................... 79
B.7.2. Monthly Line listing for Type I variations ........................................................... 79
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) ................................. 79
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) .................................................................................................................. 79
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) ........................................................................................................... 79
B.7.6. Notifications of Type I Variations (MMD only) .................................................... 79
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) ............................................................................. 79
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) ....................................................................................................................... 79
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES ....................... 79
E.1. PMF Certification Dossiers: .................................................................................... 79
E.1.1. Annual Update ................................................................................................ 79
E.1.2. Variations: ..................................................................................................... 79
E.1.3. Initial PMF Certification: .................................................................................. 79
E.2. Time Tables – starting & ongoing procedures: For information ......................... 79
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver .... 80
G. ANNEX G ............................................................................................................. 80
G.1. Final Scientific Advice (Reports and Scientific Advice letters): .......................... 80
G.2. PRIME............................................................................................................. 80
H. ANNEX H - Product Shared Mailboxes – e-mail address................................. 80
A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for March 2024: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for March 2024: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Defitelio - Defibrotide -
EMEA/H/C/002393/S/0064, Orphan
Gentium S.r.l., Rapporteur: Kristina Dunder,
PRAC Rapporteur: Mari Thorn
Positive Opinion adopted by consensus together
with the CHMP assessment report.
The Marketing Authorisation remains under
exceptional circumstances.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

Cufence - Trientine -
EMEA/H/C/004111/R/0016
Univar Solutions BV, Rapporteur: Daniela
Philadelphia, Co-Rapporteur: Konstantina
Alexopoulou, PRAC Rapporteur: Ana Sofia Diniz
Martins
Request for Supplementary Information adopted
on 25.01.2024.
Positive Opinion adopted by consensus together
with the CHMP assessment report and
translation timetable.
Based on the review of the available
information, the CHMP was of the opinion that
the renewal of the marketing authorisation can
be granted with unlimited validity.

Deferasirox Mylan - Deferasirox -
EMEA/H/C/005014/R/0013
Mylan Pharmaceuticals Limited, Generic,
Generic of EXJADE, Rapporteur: Beata Maria
Request for supplementary information adopted
with a specific timetable.
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jakline Ullrich, PRAC Rapporteur: Tiphaine Vaillant</strong></td>
<td>Request for Supplementary Information adopted on 21.03.2024.</td>
</tr>
<tr>
<td><strong>Giapreza - Angiotensin II</strong></td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
</tr>
<tr>
<td><strong>Nuceiva - Botulinum toxin type A</strong></td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
</tr>
<tr>
<td><strong>Xromi - Hydroxycarbamide</strong></td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
</tr>
<tr>
<td><strong>B.2.3. Renewals of Conditional Marketing Authorisations</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Columvi - Glofitamab</strong></td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.</td>
</tr>
<tr>
<td><strong>Lytgobi - Futibatinib</strong></td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.</td>
</tr>
<tr>
<td><strong>Rozlytrek - Entrectinib</strong></td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and</td>
</tr>
</tbody>
</table>
Gasparini, PRAC Rapporteur: Bianca Mulder

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.
The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 04-07 March 2024

PRAC:

Signal of erythema multiforme

Adopted

Abemaciclib; palbociclib; ribociclib - VERZENIOS; IBRANCE; KISQALI (CAP)

Rapporteur: Filip Josephson, Co-Rapporteur: multiple, PRAC Rapporteur: Marie Louise Schougaard Christiansen

PRAC recommendation on a variation

Action: For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its March 2024 meeting:

Dengue Tetravalent Vaccine (Live, Attenuated) Takeda - Dengue tetravalent vaccine (live, attenuated) - EMEA/H/W/005362/PSUV/0011 (without RMP)

Takeda GmbH, PRAC Rapporteur: Liana Martirosyan, "19/02/2023 to 18/08/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the Scientific Opinion for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add wording in subsection Vaccine viremia. There is no need to update the package leaflet.

EMEA/H/C/PSUSA/00010119/202307 (Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara))

CAPS:

IMVANEX (EMEA/H/C/002596) (Smallpox vaccine (live modified vaccinia virus Ankara)), Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, “31/01/2023 To: 31/07/2023”

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a
warning/precaution regarding Anxiety-related reactions and section 4.8 of the SmPC to add the adverse reaction Acute peripheral facial paralysis (Bell’s palsy) with a frequency unknown. The package leaflet is updated accordingly.

**EMEA/H/C/PSUSA/00010544/202308**

(palbociclib)

**EMEA/H/C/PSUSA/00010823/202308**

(upadacitinib)

**EMEA/H/C/PSUSA/00010843/202307**

(darolutamide)

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s):

Update of section 4.5 and 4.8 of the SmPC to add an interaction regarding palbociclib and statins; and add the adverse reaction blood creatinine increased with a frequency common. The package leaflet is updated accordingly.

Update of section 4.8 of the SmPC to add the adverse reaction vertigo with a frequency ‘common’. Update of section 4.7 of the SmPC to include vertigo. The package leaflet should be updated accordingly.

Update of section 4.8 of the SmPC to add the adverse reaction dizziness with a frequency ‘common’. Update of section 4.7 of the SmPC to include dizziness. The package leaflet should be updated accordingly.

Update of the key elements of the guide for healthcare professionals and the patient card in Annex II.D of the SmPC.
30/07/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal product(s), concerning the following change(s):

Update of sections 4.2, 4.4 and 4.8 of the SmPC to include a cross reference to section 4.4, amend a warning/precaution regarding Hepatotoxicity and amend the description of Liver function tests.

EMEA/H/C/PSUSA/00010877/202307
(leuprorelin (depot formulations))
CAPS:
Camcevi (EMEA/H/C/005034) (Leuprorelin), Accord Healthcare S.L.U., Rapporteur: Johanna Lähteenvuop
NAPS:
NAPs - EU
PRAC Rapporteur: Amelia Cupelli, "24/05/2022 To: 31/07/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of sections 4.2, 4.4 and 4.8 of the SmPC to add fatty liver to the existing warning/precaution on metabolic changes, add a warning/precaution regarding Severe cutaneous adverse reactions (SCARs) and add the adverse reaction SCARS with a frequency not known. The package leaflet is updated accordingly.

EMEA/H/C/PSUSA/00010980/202307
(anifrolumab)
CAPS:
Saphnelo (EMEA/H/C/004975) (Anifrolumab), AstraZeneca AB, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Liana Martirosyan, "30/01/2023 To: 29/07/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change:

Update of section 4.8 of the SmPC to add Arthralgia with a frequency "unknown". The package leaflet is updated accordingly.

EMEA/H/C/PSUSA/00010983/202308
(voxelotor)
CAPS:
Oxbryta (EMEA/H/C/004869) (Voxelotor), Pfizer Europe Ma EEIG, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Jo Robays, "14/02/2023 To: 13/08/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reactions: Pruritis with a frequency 'common' and angioedema with an 'unknown frequency' and as a post-marketing observation.
The package leaflet is updated accordingly.

**EMEA/H/C/PSUSA/00011034/202308**  
(dengue tetravalent vaccine (live, attenuated)  
[Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated / Dengue virus, serotype 2, live, attenuated.])

**CAPS:**  
**Qdenga** (EMEA/H/C/005155) (Dengue tetravalent vaccine (live, attenuated)), Takeda GmbH, Rapporteur: Sol Ruiz, PRAC Rapporteur: Liana Martirosyan, “18/02/2023 To: 18/08/2023”

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add wording in subsection Vaccine viremia. There is no need to update the package leaflet.

### B.4. EPARs / WPARs

#### Apremilast Accord - Apremilast - EMEA/H/C/006208


For information only. Comments can be sent to the PL in case necessary.

#### Celldemic - Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006052

Seqirus Netherlands B.V., active immunisation for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### FILSPARI - Sparsentan - EMEA/H/C/005783, Orphan

Vifor France, for the treatment of primary immunoglobulin A nephropathy (IgAN), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### Incellipan - Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006051

Seqirus Netherlands B.V., prophylaxis of influenza, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

#### Nintedanib Accord - Nintedanib -

For information only. Comments can be sent to...
| EMEA/H/C/006179 | Accord Healthcare S.L.U., treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) and lung diseases (ILDs) systemic sclerosis associated interstitial lung disease (SSc-ILD), Generic, Generic of Vargatef, Generic application (Article 10(1) of Directive No 2001/83/EC) | the PL in case necessary. |
| Pyzchiva - Ustekinumab - EMEA/H/C/006183 | Samsung Bioepis NL B.V., treatment of Crohn’s disease and Ulcerative colitis, treatment of Crohn’s disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA), Similar biological application (Article 10(4) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| Qalsody - Tofersen - EMEA/H/C/005493, Orphan | Biogen Netherlands B.V., treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| Romzurto (WD) - Ustekinumab - EMEA/H/C/006546 | Fresenius Kabi Deutschland GmbH, treatment of Crohn’s Disease, treatment of moderate to severe plaque psoriasis, active psoriatic arthritis and Crohn’s Disease, Duplicate, Duplicate of Ustekinumab Formycon, Similar biological application (Article 10(4) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| WPAR | | |
| Tizveni - Tislelizumab - EMEA/H/C/005542 | Beigene Ireland Limited, treatment of locally advanced or metastatic non-squamous non-small cell lung cancer in adults, treatment of locally advanced or metastatic squamous non-small cell lung cancer in adults, locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| Ustekinumab Formycon (duplicate) (WD) - Ustekinumab - EMEA/H/C/006541 | | For information only. Comments can be sent to the PL in case necessary. |
Formycon AG, treatment of Crohn’s disease, treatment of Plaque psoriasis, Psoriatic arthritis (PsA) and Crohn’s disease, Duplicate, Duplicate of Ustekinumab Formycon, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Voydeya - Danicopan - EMEA/H/C/005517, Orphan
Alexion Europe, Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria, New active substance (Article 8(3) of Directive No 2001/83/EC)

ZYNYZ - Retifanlimab - EMEA/H/C/006194, Orphan
Incyte Biosciences Distribution B.V., Treatment of Merkel cell carcinoma (MCC), New active substance (Article 8(3) of Directive No 2001/83/EC)

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

ASPAVELI - Pegcetacoplan - EMEA/H/C/005553/II/0015, Orphan
Swedish Orphan Biovitrum AB (publ), Rapporteur: Alexandre Moreau
Opinion adopted on 14.03.2024.
Request for Supplementary Information adopted on 25.01.2024.

BIMERVAX - SARS-CoV-2, variant XBB.1.16, spike protein, receptor binding domain fusion homodimer / Selvacovatein - EMEA/H/C/006058/II/0007/G
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich
Opinion adopted on 07.03.2024.
Request for Supplementary Information adopted on 18.01.2024, 16.11.2023, 05.10.2023.

Braftovi - Encorafenib - EMEA/H/C/004580/II/0035/G
Pierre Fabre Medicament, Rapporteur: Janet Koenig
Request for supplementary information adopted with a specific timetable.
<table>
<thead>
<tr>
<th>Product/Brand Name</th>
<th>Action/Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEA/H/C/005735/II/0202</td>
<td></td>
</tr>
<tr>
<td>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson</td>
<td></td>
</tr>
<tr>
<td>Opinion adopted on 29.02.2024.</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted on 25.01.2024.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/005735/II/0205</td>
<td></td>
</tr>
<tr>
<td>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson</td>
<td></td>
</tr>
<tr>
<td>Opinion adopted on 14.03.2024.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Dovprela - Pretomanid</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
</tr>
<tr>
<td>EMEA/H/C/005167/II/0020, Orphan</td>
<td></td>
</tr>
<tr>
<td>Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted on 07.03.2024.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Empliciti - Elotuzumab</td>
<td>Positive Opinion adopted by consensus on 21.03.2024.</td>
</tr>
<tr>
<td>EMEA/H/C/003967/II/0037/G</td>
<td></td>
</tr>
<tr>
<td>Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol</td>
<td></td>
</tr>
<tr>
<td>Opinion adopted on 21.03.2024.</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted on 15.02.2024.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrylaze - Crisantaspase</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
</tr>
<tr>
<td>EMEA/H/C/005917/II/0003/G</td>
<td></td>
</tr>
<tr>
<td>Jazz Pharmaceuticals Ireland Limited, Rapporteur: Peter Mol</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted on 14.03.2024.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Eptifibatide Accord - Eptifibatide</td>
<td>Positive Opinion adopted by consensus on 21.03.2024.</td>
</tr>
<tr>
<td>EMEA/H/C/004104/II/0015/G</td>
<td></td>
</tr>
<tr>
<td>Accord Healthcare S.L.U., Generic, Generic of Integrilin, Rapporteur: Jayne Crowe</td>
<td></td>
</tr>
<tr>
<td>Opinion adopted on 21.03.2024.</td>
<td></td>
</tr>
<tr>
<td>Request for Supplementary Information adopted on 08.02.2024, 26.10.2023, 12.05.2023.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>EXPAREL liposomal - Bupivacaine</td>
<td>Positive Opinion adopted by consensus on 21.03.2024.</td>
</tr>
<tr>
<td>EMEA/H/C/004586/II/0018</td>
<td></td>
</tr>
<tr>
<td>Pacira Ireland Limited, Rapporteur: Elita Poplavska</td>
<td></td>
</tr>
<tr>
<td>Opinion adopted on 21.03.2024.</td>
<td></td>
</tr>
</tbody>
</table>
Request for Supplementary Information adopted on 25.01.2024.

**Foclivia - Pandemic Influenza vaccine (surface antigen, inactivated, adjuvanted)** - EMEA/H/C/001208/II/0084/G
Seqirus S.r.l, Rapporteur: Maria Grazia Evandri
Opinion adopted on 29.02.2024.
Request for Supplementary Information adopted on 11.01.2024.

Positive Opinion adopted by consensus on 29.02.2024.

**Gliolan - 5-aminolevulinic acid** - EMEA/H/C/000744/II/0026/G
Photonamic GmbH & Co. KG, Rapporteur: Bruno Sepodes
Opinion adopted on 14.03.2024.
Request for Supplementary Information adopted on 11.01.2024.

Positive Opinion adopted by consensus on 14.03.2024.

**Hetlioz - Tasimelteon** - EMEA/H/C/003870/II/0037, Orphan
Vanda Pharmaceuticals Netherlands B.V., Rapporteur: Jayne Crowe
Opinion adopted on 14.03.2024.
Request for Supplementary Information adopted on 08.02.2024.

Positive Opinion adopted by consensus on 14.03.2024.

**Hizentra - Human normal immunoglobulin** - EMEA/H/C/002127/II/0150/G
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 21.03.2024.

Request for supplementary information adopted with a specific timetable.

**Ibandronic Acid Teva - Ibandronic acid** - EMEA/H/C/001195/II/0021
Teva B.V., Generic, Generic of Bondronat, Bonviva, Rapporteur: Hrefna Gudmundsdottir

Request for supplementary information adopted with a specific timetable.

**Ilumetri - Tildrakizumab** - EMEA/H/C/004514/II/0052
Almirall S.A, Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 29.02.2024.

Positive Opinion adopted by consensus on 29.02.2024.

**Kanuma - Sebelipase alfa** - EMEA/H/C/004004/II/0048, Orphan
Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn
Opinion adopted on 14.03.2024.

Positive Opinion adopted by consensus on 14.03.2024.
<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA/H/C/XX/YY/ZZ/AA/G</th>
<th>Company</th>
<th>Rapporteur</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keytruda – Pembrolizumab - EMEA/H/C/003820/II/0149</td>
<td>Merck Sharp &amp; Dohme B.V., Rapporteur: Paolo Gasparini</td>
<td>Request for Supplementary Information adopted on 07.03.2024.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kovaltry – Octocog alfa - EMEA/H/C/003825/II/0044/G</td>
<td>Bayer AG, Rapporteur: Kristina Dunder</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicine</td>
<td>EMEA Number</td>
<td>Rapporteur</td>
<td>Opinion Date</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>Nulojix - Belatacept</td>
<td>EMEA/H/C/002098/II/0090/G</td>
<td>Filip Josephson</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>29.02.2024.</td>
</tr>
<tr>
<td>Pedmarqsi - Sodium thiosulfate</td>
<td>EMEA/H/C/005130/II/0002/G</td>
<td>Elita Poplavska</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>21.03.2024.</td>
</tr>
<tr>
<td>Rotarix - Rotavirus vaccine (live, oral)</td>
<td>EMEA/H/C/000639/II/0132/G</td>
<td>Christophe Focke</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>14.03.2024.</td>
</tr>
<tr>
<td>Skytrofa - Lonapegsomatropin</td>
<td>EMEA/H/C/005367/II/0024, Orphan</td>
<td>Patrick Vrijlandt</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>07.03.2024.</td>
</tr>
<tr>
<td>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified)</td>
<td>EMEA/H/C/005791/II/0116/G</td>
<td>Jan Mueller-Berghaus</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>07.03.2024.</td>
</tr>
<tr>
<td>Supemtek - Influenza quadrivalent vaccine (rDNA)</td>
<td>EMEA/H/C/005159/II/0013/G</td>
<td>Jan Mueller-Berghaus</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>14.03.2024.</td>
</tr>
<tr>
<td>TachoSil - Human thrombin / Human fibrinogen</td>
<td>EMEA/H/C/000505/II/0125/G</td>
<td>Jan Mueller-Berghaus</td>
<td>Positive Opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>adopted by consensus on</td>
<td>29.02.2024.</td>
</tr>
</tbody>
</table>

Request for Supplementary Information adopted on 11.01.2024.
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Therapeutic Area</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TRODELVY - Sacituzumab govitecan -</strong></td>
<td><strong>EMEA/H/C/005182/II/0030/G</strong></td>
<td><strong>Request for supplementary information adopted with a specific timetable.</strong></td>
</tr>
<tr>
<td>Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
<td><strong>Request for Supplementary Information adopted on 21.03.2024.</strong></td>
</tr>
<tr>
<td><strong>Tysabri - Natalizumab -</strong></td>
<td><strong>EMEA/H/C/000603/II/0141/G</strong></td>
<td><strong>Positive Opinion adopted by consensus on 07.03.2024.</strong></td>
</tr>
<tr>
<td>Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
<td><strong>Opinion adopted on 07.03.2024.</strong></td>
</tr>
<tr>
<td><strong>Vitrolife IVF media - Recombinant human albumin solution -</strong></td>
<td><strong>EMEA/H/D/004693/II/0005</strong></td>
<td><strong>Request for supplementary information adopted with a specific timetable.</strong></td>
</tr>
<tr>
<td>Vitrolife Sweden AB, Rapporteur: Maria Grazia Evandri</td>
<td></td>
<td><strong>Request for Supplementary Information adopted on 14.03.2024.</strong></td>
</tr>
<tr>
<td><strong>Yargesa - Miglustat -</strong></td>
<td><strong>EMEA/H/C/004016/II/0014</strong></td>
<td><strong>Request for supplementary information adopted with a specific timetable.</strong></td>
</tr>
<tr>
<td>Piramal Critical Care B.V., Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphy</td>
<td></td>
<td><strong>Request for Supplementary Information adopted on 21.03.2024.</strong></td>
</tr>
<tr>
<td><strong>Zometa - Zoledronic acid -</strong></td>
<td><strong>EMEA/H/C/000336/II/0103/G</strong></td>
<td><strong>Request for supplementary information adopted with a specific timetable.</strong></td>
</tr>
<tr>
<td>Phoenix Labs Unlimited Company, Rapporteur: Thalia Marie Estrup Blicher</td>
<td></td>
<td><strong>Request for Supplementary Information adopted on 21.03.2024.</strong></td>
</tr>
<tr>
<td><strong>Zoonotic Influenza Vaccine Seqirus - Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) -</strong></td>
<td><strong>EMEA/H/C/006375/II/0001</strong></td>
<td><strong>Positive Opinion adopted by consensus on 21.03.2024.</strong></td>
</tr>
<tr>
<td>Seqirus S.r.l., Informed Consent of Aflunov, Rapporteur: Maria Grazia Evandri</td>
<td></td>
<td><strong>Opinion adopted on 21.03.2024.</strong></td>
</tr>
<tr>
<td><strong>WS2596</strong></td>
<td><strong>Infanrix hexa-</strong></td>
<td><strong>Positive Opinion adopted by consensus on 14.03.2024.</strong></td>
</tr>
<tr>
<td>GlaxoSmithkline Biologicals SA, Lead</td>
<td></td>
<td><strong>Positive Opinion adopted by consensus on 14.03.2024.</strong></td>
</tr>
<tr>
<td><strong>Zoonotic Influenza Vaccine Seqirus -</strong></td>
<td><strong>Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) -</strong></td>
<td><strong>Positive Opinion adopted by consensus on 21.03.2024.</strong></td>
</tr>
<tr>
<td><strong>WS2596</strong></td>
<td><strong>Infanrix hexa-</strong></td>
<td><strong>Positive Opinion adopted by consensus on 14.03.2024.</strong></td>
</tr>
</tbody>
</table>
Rapporteur: Christophe Focke  
Opinion adopted on 14.03.2024.

<table>
<thead>
<tr>
<th><strong>WS2630</strong></th>
<th><strong>Hefiya-EMEA/H/C/004865/WS2630/0052</strong></th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyrimoz-EMEA/H/C/004320/WS2630/0051</strong></td>
<td>Sandoz GmbH, Lead Rapporteur: Christian Gartner</td>
<td>Request for Supplementary Information adopted on 07.03.2024.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>WS2638</strong></th>
<th><strong>Luveris-EMEA/H/C/000292/WS2638/0098</strong></th>
<th>Positive Opinion adopted by consensus on 14.03.2024.</th>
</tr>
</thead>
</table>

**B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

<table>
<thead>
<tr>
<th><strong>AREXVY - Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E - EMEA/H/C/006054/II/0002/G</strong></th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlaxoSmithkline Biologicals S.A., Rapporteur: Patrick Vrijlandt, &quot;Update of section 4.5 of the SmPC in order to update information on the co-administration with inactivated seasonal quadrivalent influenza vaccines: with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV) based on final results from studies RSV OA=ADJ-008 and RSV OA=ADJ-017. These are Phase III studies intended to evaluate the immune response, safety and reactogenicity of Arexvy when co-administered with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV), respectively.&quot;</td>
<td>Request for Supplementary Information adopted on 07.03.2024, 09.11.2023.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BIMERVAX - SARS-CoV-2, variant XBB.1.16, spike protein, receptor binding domain fusion homodimer / Selvacovatein - EMEA/H/C/006058/II/0013</strong></th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, &quot;Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to change...&quot;</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
</tr>
</tbody>
</table>
posology recommendations in individuals 16 years of age and older, amend an existing warning on hypersensitivity and anaphylaxis, delete insomnia and back pain from the list of adverse drug reactions (ADRs), change frequency of odynophagia, abdominal pain and injection site hypersensitivity from Uncommon to Rare and update immunogenicity information based on final results from study HIPRA-HH-2 (PART A and PART B) listed as a category 3 study in the RMP; HIPRA-HH-2 was a Phase IIb, double-blind, randomised, active-controlled, multi-centre, non-inferiority trial in adults fully vaccinated against COVID-19. The objective was to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion heterodimer vaccine candidate (PHH-1V) against SARS-CoV-2 (Part A). An extension to the study was introduced to add a fourth dose as described below (Part B).” Request for Supplementary Information adopted on 21.03.2024.

**Bimzelx - Bimekizumab - EMEA/H/C/005316/II/0025**

UCB Pharma S.A., Rapporteur: Finbarr Leacy, “Update of section 5.1 of the SmPC in order to add long-term efficacy data based on the interim results (week 144 data) from study PS0014 listed as a category 3 study in the RMP (MEA/005); this is an ongoing, multicenter, open-label extension (OLE) study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate to severe plaque PSO who completed 1 of the 3 completed feeder studies (PS0008, PS0009 and PS0013).” Request for Supplementary Information adopted on 21.03.2024, 25.01.2024.

**Cablivi - Caplacizumab - EMEA/H/C/004426/II/0048, Orphan**

Ablynx NV, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information on paediatric patients based on results from study OBS17325 - Retrospective Data Collection of Pediatric Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) Treated with Caplacizumab. The primary objective of this study was to describe the...” Request for supplementary information adopted with a specific timetable.
effectiveness and safety of caplacizumab in pediatric patients with iTTP.”
Request for Supplementary Information adopted on 14.03.2024.

<table>
<thead>
<tr>
<th><strong>COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified)</strong></th>
<th>Positive Opinion adopted by consensus on 14.03.2024.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMEA/H/C/005735/II/0203</strong></td>
<td><strong>BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson,</strong> “Update of section 4.8 of the SmPC in order to update the safety information based on interim (6MPD3 in 6mo-12yo) results from study C4591007, listed as a category 3 study in the RMP. This is an interventional &quot;Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children.”” Opinion adopted on 14.03.2024.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cyramza - Ramucirumab</strong></th>
<th>Positive Opinion adopted by consensus on 21.03.2024.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMEA/H/C/002829/II/0053</strong></td>
<td><strong>Eli Lilly Nederland B.V., Rapporteur: Peter Mol,</strong> “Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety data on paediatric patients following the outcome of Article 46 procedure EMEA/H/C/002829/P46/009 and based on results from study J1S-MC-JV02 (JV02). This is a randomized, open-label, phase 1/2 study evaluating ramucirumab in paediatric patients and young adults with relapsed, recurrent, or refractory synovial sarcoma. In addition, the MAH took the opportunity to implement editorial updates to the SmPC and the Package Leaflet.” Opinion adopted on 21.03.2024.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Duavive - Estrogens conjugated / Bazedoxifene</strong></th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMEA/H/C/002314/II/0036</strong></td>
<td><strong>Pfizer Europe MA EEIG, Rapporteur: Martina Weise,</strong> “Update of section 4.4 of the SmPC in order to update the wording regarding interactions with other medicinal products and to align with the updated CMDh Core SmPC. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with</td>
</tr>
</tbody>
</table>
the latest QRD template version 10.3."
Request for Supplementary Information adopted on 14.03.2024.

**Dupixent - Dupilumab - EMEA/H/C/004390/II/0078**
Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.2 of the SmPC in order to allow the use of the Dupixent Prefilled Pen presentations for patients aged 2 to < 12 years of age based on final results of the R668-AD-1434 sub-study; this is an interventional open-label sub-study which purpose is to evaluate the PK, safety, immunogenicity, and efficacy of repeat doses of dupilumab (200 mg Q4W, 300 mg Q4W, and 200 mg Q2W) administered SC using a PFP with a skin pinch in children ≥2 to < 12 years of age. The Package Leaflet is updated accordingly. In addition, the MA took the opportunity to update the list of local representatives in the Package Leaflet.”
Opinion adopted on 21.03.2024.

**Epidyolex - Cannabidiol - EMEA/H/C/004675/II/0028/G, Orphan**
Jazz Pharmaceuticals Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, "Grouped application comprising three type II variations (C.I.13) as follows:
- Submission of the final report from study GWTX21068 – Genotoxicity study with 7-OH-CBD (Bacterial Reverse Mutation Assay). The objective of this study was to evaluate the ability of GWP4200370 (also known as 7-COOH-CBD) to induce reverse mutations in five histidine-requiring strains of Salmonella typhimurium in the absence and presence of a rat liver metabolizing system (S-9).
- Submission of the final report from study GWTX21028 – Genotoxicity study with 7-COOH-CBD (Bacterial Reverse Mutation Assay). The objective of this study was to evaluate the ability of GWP4200307 to induce reverse mutations in five histidine-requiring strains of Salmonella typhimurium in the absence and presence of a rat liver metabolizing system (S-9).
- Submission of the final report from

Positive Opinion adopted by consensus on 21.03.2024.
GWTX18015 – Genotoxicity study with 7-COOH-CBD (Rat Micronucleus and Alkaline Comet Assay). The objective of this study was to evaluate the ability of GWP4200370 (also known as 7-COOH-CBD) to induce reverse mutations in five histidine-requiring strains of Salmonella typhimurium in the absence and presence of a rat liver metabolizing system (S-9).”
Opinion adopted on 14.03.2024.
Request for Supplementary Information adopted on 23.11.2023.

**Fabrazyme - Agalsidase beta - EMEA/H/C/000370/II/0129**
Sanofi B.V., Rapporteur: Patrick Vrijlandt,
"Update of section 4.6 of the SmPC in order to update the safety information on pregnancy and breast-feeding based on results from AGAL02603/MSC12868: "A Multicenter, Multinational Study of the Effects of Fabrazyme (agalsidase beta) Treatment on Lactation and Infants", listed as a category 3 study in the RMP, MAH safety database and literature search; the Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce minor editorial changes to the PI.”
Opinion adopted on 14.03.2024.

**Gardasil 9 - Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0069**
Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update long-term effectiveness information based on results from the 4th interim report for study V503-021, listed as a category 3 study in the RMP. This is a registry-based extension of protocol V503-001 in countries with centralized cervical cancer screening infrastructures to evaluate the long-term effectiveness, immunogenicity, and safety of 9vHPV vaccine as administered to 16- to 26-year-old women. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.”
Opinion adopted on 21.03.2024.
Request for Supplementary Information adopted on 25.01.2024.

**Jakavi - Ruxolitinib - EMEA/H/C/002464/II/0068**

Novartis Europharm Limited, Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC in order to add new warnings on 'Major adverse cardiac events (MACE)', 'Thrombosis', and 'Second primary malignancies', following an Art. 20 Class Referral involving JAK inhibitors approved to treat rheumatoid arthritis. The PIL is updated accordingly."

Opinion adopted on 21.03.2024.
Request for Supplementary Information adopted on 25.01.2024, 12.10.2023.

**JCOVDEN - COVID-19 Vaccine Janssen (Ad26.COV2.S) - EMEA/H/C/005737/II/0075/G**

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "A grouped application consisting of five Type II variations, as follows:

C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on results on updated genomic sequencing data from study VAC31518COV3001 listed as a category 3 study in the RMP. This is a randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to section 6.1 of the SmPC and to the Package Leaflet.

C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on results on updated genomic sequencing data from study VAC31518COV3009 listed as a category 3 study in the RMP. This is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, reactogenicity, and immunogenicity of 2 doses of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older.

C.I.13: Submission of the final report from VAC31518COV2008 listed as a category 3 study in the RMP. This is a randomized, double-blind,
Phase 2 study to evaluate the immunogenicity, reactogenicity and safety of Ad26.COV2.S administered as booster vaccination in adults 18 years of age and older who have previously received primary vaccination with Ad26.COV2.S or BNT162b2.

C.I.13: Submission of the final report from the open label phase of study VAC31518COV3001 listed as a category 3 study in the RMP.

C.I.13: Submission of the final report from VAC31518COV4002 listed as a category 3 study in the RMP. This is an observational post-authorisation study to assess the effectiveness of Ad26.COV2.S for prevention of COVID-19 using real-world data.”

Opinion adopted on 21.03.2024.

Kalydeco - Ivacaftor - EMEA/H/C/002494/II/0124
Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, "Submission of the final report from Post-Authorisation Effectiveness Study (PAES) VX15-770-125 listed as a category 3 study in the RMP (ANX/024). This is an observational study to evaluate the long-term effectiveness and safety of kalydeco in children with cystic fibrosis who have a specified CFTR gating mutation and are aged 2 through 5 years at therapy initiation."
Request for Supplementary Information adopted on 14.03.2024.

Keytruda - Pembrolizumab - EMEA/H/C/003820/II/0147
Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-B61; this is a Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC)."
Positive Opinion adopted by consensus on 14.03.2024.

Kisplyx - Lenvatinib - EMEA/H/C/004224/II/0058
Eisai GmbH, Rapporteur: Karin Janssen van Doorn, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-B61; this is a Positive Opinion adopted by consensus on 14.03.2024.
<table>
<thead>
<tr>
<th>Product Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leqvio - Inclisiran - EMEA/H/C/005333/II/0022</td>
<td>Novartis Europharm Limited, Rapporteur: Martina Weise, &quot;Update of the Package Leaflet (Annex III.B) in order to include complete Instructions For Use for Healthcare Professionals for the pre-filled syringe without needle guard and to update the Instructions For Use for Healthcare Professionals for the pre-filled with needle guard.&quot; Opinion adopted on 14.03.2024. Positive Opinion adopted by consensus on 14.03.2024.</td>
</tr>
<tr>
<td>LIVTENCITY - Maribavir - EMEA/H/C/005787/II/0008, Orphan</td>
<td>Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Janet Koenig, &quot;Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the updated Population PK analysis data. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.&quot; Opinion adopted on 21.03.2024. Request for Supplementary Information adopted on 16.11.2023. Positive Opinion adopted by consensus on 21.03.2024.</td>
</tr>
<tr>
<td>Myozyme - Alglucosidase alfa - EMEA/H/C/000636/II/0098</td>
<td>Sanofi B.V., Rapporteur: Alexandre Moreau, &quot;To update section 4.8 of the SmPC to add burning sensation, syncope and asthma to the list of adverse drug reactions (ADRs) with frequency common, not known and not known respectively, following the assessment of procedure II/93 based on the cumulative review of clinical studies, MAH safety database and literature search. The Package Leaflet is updated accordingly.&quot; Opinion adopted on 14.03.2024. Positive Opinion adopted by consensus on 14.03.2024.</td>
</tr>
</tbody>
</table>
Leacy, “A grouped application comprised of two type II variations, as follows:

C.I.4: Update of section 4.5 of the SmPC in order to remove the recommendation for close monitoring for adverse events with concomitant use of P-gp and BCRP inhibitors based on final safety results from the drug-drug interaction study BCX7353-119, as well as to update the effects of cyclosporine on berotralstat. Study BCX7353-119 is a phase 1 drug-drug interaction study to evaluate the effect of cyclosporine on the pharmacokinetics of berotralstat in healthy subjects.

C.I.13: Submission of the final reports from parts 2 and 3 of study BCX7353-301; this is a phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the suppression of events in subjects with hereditary angioedema.

In addition, the MAH took the opportunity to add additional wording for patients with severely reduced kidney function in the Package Leaflet and to introduce minor editorial changes to the PI, as per previous guidance.”

Request for Supplementary Information adopted on 21.03.2024.

**QUVIVIQ - Daridorexant - EMEA/H/C/005634/II/0013/G**

Idorsia Pharmaceuticals Deutschland GmbH, Rapporteur: Alexandre Moreau, "Update of sections 4.4, 4.5 and 5.1 of the SmPC in order to reflect the conclusions of studies ID-075-121, ID-078-122 and ID-078-118, respectively. The Package Leaflet was updated accordingly. Study ID-078-121 is a randomized, double-blind, placebo-controlled, 2-way crossover study to investigate the effects of daridorexant on nighttime respiratory function and sleep in subjects with severe obstructive sleep apnea; Study ID-078-122 is a prospective, open-label, single-dose Phase 1 study to measure daridorexant in breast milk of healthy lactating women; and Study ID-078-118 is a single-center, randomized, double-blind, single-dose, 3-way crossover study to compare the effects of daridorexant and placebo on postural stability, the auditory awakening threshold, and cognitive function in the middle of the night following Request for supplementary information adopted with a specific timetable.
evening administration to healthy adult and elderly subjects."
Request for Supplementary Information adopted on 07.03.2024, 01.02.2024.

**Remsima - Infliximab**
**EMEA/H/C/002576/II/0133/G**
Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, "Grouped application comprising three type II variations (C.I.4) as follows:
- Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (crohn’s disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease.
- Update of sections 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (> 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study).
The RMP version 16.1 has also been submitted. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI."

See 9.1
Request for supplementary information adopted with a specific timetable.
| **Repatha - Evolocumab** -  
**EMEA/H/C/003766/II/0069** | Request for supplementary information adopted with a specific timetable.  
Amgen Europe B.V., Rapporteur: Patrick Vrijlandt, "Update of section 5.1 of the SmPC to include Real World Data information based on final results from study 20130296; this is an observational study to describe the clinical characteristics of patients on initiation of Repatha, with a secondary objective to describe the treatment patterns of Repatha use over time.”  
Request for Supplementary Information adopted on 14.03.2024. |
|---|---|
| **RINVOQ - Upadacitinib** -  
**EMEA/H/C/004760/II/0045** | Positive Opinion adopted by consensus on 29.02.2024.  
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Submission of the final report from study M15-555, listed as a category 3 study in the RMP. This is phase 3, randomized, double-blind study comparing upadacitinib (ABT-494) monotherapy to methotrexate (MTX) in subjects with moderately to severely active rheumatoid arthritis with inadequate response to MTX.”  
Opinion adopted on 29.02.2024.  
| **RINVOQ - Upadacitinib** -  
**EMEA/H/C/004760/II/0049** | Request for supplementary information adopted with a specific timetable.  
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to include long term efficacy and safety information (up to week 104 data) from study M19-944 (study 2); this is a phase 3, randomized, double-blind study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with nr-axSpA who completed the double-blind period on study drug.”  
Request for Supplementary Information adopted on 14.03.2024. |
| **Rivastigmine 1A Pharma - Rivastigmine** -  
**EMEA/H/C/001181/II/0042** | Request for supplementary information adopted with a specific timetable.  
1 A Pharma GmbH, Informed Consent of Exelon, Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.5 of the SmPC in order to add a new warning on the risk of QT.”  
|
prolongation based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”
Request for Supplementary Information adopted on 21.03.2024.

**Rivastigmine HEXAL - Rivastigmine - EMEA/H/C/001182/II/0042**
Hexal AG, Informed Consent of Exelon, Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.5 of the SmPC in order to add a new warning on the risk of QT prolongation based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”
Request for Supplementary Information adopted on 21.03.2024.

**Rivastigmine Sandoz - Rivastigmine - EMEA/H/C/001183/II/0042**
Sandoz GmbH, Informed Consent of Exelon, Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.5 of the SmPC in order to add a new warning on the risk of QT prolongation based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”
Request for Supplementary Information adopted on 21.03.2024.

**Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0014**
Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, “Submission of the final report from study R10933-10987-COV-2118 (COV-2118) - A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered with Casirivimab+Imdevimab in Healthy Adult Volunteers.”
Opinion adopted on 29.02.2024.
Request for Supplementary Information adopted on 11.01.2024.

**Scemblix - Asciminib -**
Positive Opinion adopted by consensus on 29.02.2024.
**EMEA/H/C/005605/II/0009, Orphan**

Novartis Europharm Limited, Rapporteur: Janet Koenig, "Update of section 5.3 of the SmPC in order to update preclinical safety data based on final results from study R1570226: this is a 2-year rat carcinogenicity study. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

Opinion adopted on 29.02.2024.


---

**Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0121/G**

Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus, "A grouped application consisting of three Type II variations, as follows:

C.I.4: Update of sections 4.5, 4.8 and 5.1 of the SmPC to add drug-drug interaction information of Coadministration of Spikevax (mRNA-1273), including its variant formulations with herpes zoster (shingles) vaccine, based on final results from Clinical Study 217670 (NCT05047770). This is a phase 3, randomized, open-label, controlled, multi-center clinical study to evaluate the immune response and safety of both herpes zoster subunit vaccine (HZ/su or Shingrix) in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine (Flu D-QIV or Fluarix Quadrivalent) in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-1273 booster vaccination.

C.I.4: Update of sections 4.5, 4.8 and 5.1 of the SmPC to add drug-drug interaction information of Coadministration of Spikevax (mRNA-1273), including its variant formulations with influenza vaccines (standard), based on final results from Clinical Study 217670 (NCT05047770). This is a phase 3, randomized, open-label, controlled, multi-center clinical study, sponsored by GlaxoSmithKline Biologicals, to evaluate the immune response and safety of both herpes zoster subunit vaccine (HZ/su or Shingrix) in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine (Flu D-QIV or Fluarix Quadrivalent) in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-
1273 booster vaccination.

C.1.4: Update of sections 4.5, 4.8 and 5.1 of the SmPC to add drug-drug interaction information of Coadministration of the variants of Spikevax (mRNA-1273) with influenza (high-dose) vaccines, based on final results from Clinical Study QHD00028 (NCT04969276). This is a Phase II, open-label study, to 'Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine'.

Request for Supplementary Information adopted on 21.03.2024.

**Tevimbra - Tislelizumab -**
**EMEA/H/C/005919/II/0002**

Beigene Ireland Limited, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.4 and 4.8 of the SmPC in order to update an existing warning and add ‘Stevens-Johnson Syndrome (SJS)’ and ‘Toxic epidermal necrolysis (TEN)’ to the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Opinion adopted on 21.03.2024.

**Trumenba - Meningococcal group B vaccine (recombinant, adsorbed) -**
**EMEA/H/C/004051/II/0052**

Pfizer Europe MA EEIG, Rapporteur: Patrick Vrijlandt, "Update of sections 4.2 and 4.8 of the SmPC in order to add information regarding fever in infants 2 months of age based on final results from study C3511002; this is a Phase 2b trial to assess the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age. In addition, the MAH is taking this opportunity to implement a minor editorial update to SmPC section 4.4 to add a ‘Traceability’ subheading, in line with the QRD product information template version 10.3. Furthermore, as suggested in the linguistic review phase of variation procedure EMEA/H/C/004051/II/0037, the MAH is adding an 'Excipients' subheading to SmPC section.

Request for supplementary information adopted with a specific timetable.
### Ultomiris - Ravulizumab - EMEA/H/C/004954/II/0043/G

Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez, "A grouped application comprised of a Type II Variation and a Type IA Variation, as follows:

Type II (C.I.4): Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update clinical information regarding the atypical haemolytic uraemic syndrome (aHUS) indication, based on final results from studies ALXN1210-aHUS-311 and ALXN1210-aHUS-312. ALXN1210-aHUS-311 is a phase 3, open-label, uncontrolled, multicenter, single treatment arm study in adolescent and adult patients with evidence of TMA who are naïve to complement inhibitor treatment, while ALXN1210-aHUS-312 is a phase 3, open-label, uncontrolled, multicenter, single treatment arm study in pediatric patients with evidence of TMA who are naïve to complement inhibitor treatment (Cohort 1) or are clinically stable after having been treated with eculizumab (Cohort 2). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.

Type IA (A.6): To change the ATC Code for ravulizumab from L04AA43 to L04AJ02."

Request for Supplementary Information adopted on 21.03.2024.

### Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0099

AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the final report from study D8111R00017 (COVIDRIVE) listed as a category 3 PAES in the RMP. This is a post-authorisation retrospective cohort study to evaluate the effectiveness of the AZD1222 vaccine to prevent serious COVID-19 infection in conditions of usual care."

Opinion adopted on 14.03.2024.

### Veklury - Remdesivir - EMEA/H/C/005622/II/0054/G

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped application to update section

Positive Opinion adopted by consensus on 14.03.2024.
5.2 of the SmPC to update pharmacokinetic information based on results from two Population PK Study reports, QP-2023-1074 and CTRA-2023-1084. QP-2023-1074 is a population pharmacokinetic analysis of Sulfobutylether-β-cyclodextrin (SBECD) in adults with normal and impaired renal function following remdesivir administration. CTRA-2023-1084 is a population pharmacokinetic analysis for remdesivir and metabolites (GS-704277 and GS-441524) after administration of remdesivir in adults.”

Request for Supplementary Information adopted on 14.03.2024.

**Venclyxto - Venetoclax** -
**EMEA/H/C/004106/II/0047**
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC following submission of the final report from study GO28667 (MURANO) listed as a category 3 study in the RMP. This is a Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared with Bendamustine Plus Rituximab.”
Opinion adopted on 21.03.2024.
Request for Supplementary Information adopted on 08.02.2024.

**Volibris - Ambrisentan** -
**EMEA/H/C/000839/II/0067**
GlaxoSmithKline (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, “To update sections 4.8 and 5.1 of the SmPC following the assessment of Art 46 procedure (EMEA/H/C/000839) based on final results from study AMB114588; this is an open-label, long-term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired. In addition, the MAH took the opportunity to implement minor editorial changes to Annex II and to the Package Leaflet.”
Opinion adopted on 14.03.2024.
Request for Supplementary Information adopted on 11.01.2024.

**Xeljanz - Tofacitinib** -
Request for supplementary information adopted
**EMEA/H/C/004214/II/0059**
Pfizer Europe MA EEIG, Rapporteur: Paolo Gasparini, "Update of section 4.4 of the SmPC in order to update serious infections section based on post-marketing data and literature. In addition, the MAH has taken the opportunity to implement changes to improve readability and to update the list of local representatives in the Package Leaflet."
Request for Supplementary Information adopted on 14.03.2024.

**ZTALMY - Ganaxolone - EMEA/H/C/005825/II/0002, Orphan**
Marinus Pharmaceuticals Emerald Limited, Rapporteur: Peter Mol, "Submission of the final report from study 1042-HME-1001 listed as post-authorisation measure (PAM) recommendation. This is an interventional Phase 1 Single Dose, Open-Label Crossover Comparative Bioavailability Study of Two Oral Formulations of Ganaxolone. The primary objective of this study was to evaluate and compare the pharmacokinetics of a new ganaxolone formulation (hot-melt extrusion [HME]) with ganaxolone oral suspension after a single oral dose administration under fed conditions."

**WS2603**
**Eucreas-**
EMEA/H/C/000807/WS2603/0105
**Galvus-**
EMEA/H/C/000771/WS2603/0082
**Icandra-**
EMEA/H/C/001050/WS2603/0110
**Jalra-**
EMEA/H/C/001048/WS2603/0085
**Xiliarx-**
EMEA/H/C/001051/WS2603/0083
**Zomarist-**
EMEA/H/C/001049/WS2603/0107
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add 'Cholecystitis' to the list of adverse drug reactions (ADRs) with frequency 'Not known'. The Package Leaflet is updated accordingly."
Opinion adopted on 29.02.2024.
Request for Supplementary Information adopted on 11.01.2024.

**WS2626**
**Positive Opinion adopted by consensus on 29.02.2024.**
**Mirapexin-**
EMEA/H/C/000134/WS2626/0107

**Sifrol-EMEA/H/C/000133/WS2626/0098**
Boehringer Ingelheim International GmbH, Lead Rapporteur: Thalia Marie Estrup Blicher,

"Update of section 4.8 of the SmPC in order to add ‘spontaneous penile erection’ to the list of adverse drug reactions (ADRs) with frequency rare, based on the outcome of a cumulative review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, introduce minor editorial changes to the PI and bring it in line with the updated QRD template version 10.3."

Opinion adopted on 14.03.2024.

---

**B.5.3. CHMP-PRAC assessed procedures**

**Beyfortus - Nirsevimab -**
EMEA/H/C/005304/II/0018/G
Sanofi Winthrop Industrie, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Kimmo Jaakkola, "Grouped application comprising two type II variations as follows:

C.I.13: Submission of the final report from study D5290C00004 (MELODY) listed as a category 3 study in the RMP. This is a phase III study, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of MEDI8897, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants.

C.I.13: Submission of the final report from study D5290C00005 (MEDLEY) listed as a category 3 study in the RMP. This is a phase II/III study, randomized, double-blind, placebo-controlled study to evaluate the safety of Beyfortus (nirsevimab) in high-risk children. The RMP version 2.3 has also been submitted."

Request for Supplementary Information adopted on 07.03.2024, 08.02.2024.

**COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -**
EMEA/H/C/005735/II/0201
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Liana Martirosyan, "Update of sections 4.5, 4.8 and

Request for supplementary information adopted with a specific timetable.
5.1 of the SmPC in order to update information regarding concomitant vaccine administration with influenza vaccine based on final results from study C4591030 listed as a category 3 study in the RMP. This is an interventional phase 3, randomized, observer-blind trial to evaluate the safety and immunogenicity of BNT162b2 and quadrivalent seasonal influenza vaccine when administered separately or concomitantly in adults 18 to 64 years of age. The Package Leaflet is updated accordingly. The RMP version 11.1 has also been submitted.”

Request for Supplementary Information adopted on 07.03.2024.

Dovprela - Pretomanid -
EMEA/H/C/005167/II/0019/G, Orphan
Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Liana Martirosyan, “Grouped application comprising two variations as follows:
Type II (C.I.4) – Update of sections 4.1 and 5.1 of the SmPC in order to rephrase the indication wording to align with the current WHO definitions. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.
Type IB (C.I.11.z) - Submission of an updated RMP version 2.0 in order to align the safety concerns following the assessment of procedure EMEA/H/C/005167/11/0013.”

Request for Supplementary Information adopted on 07.03.2024.

Fintepla - Fenfluramine -
EMEA/H/C/003933/II/0022/G, Orphan
UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, “A grouped application comprised of three Type II variations, as follows:
C.I.4: Update of sections 4.4 and 4.8 of the SmPC in order to modify the list of adverse drug reactions based on a revised safety ADR methodology for Dravet and Lennox-Gastaut syndromes, which includes pooled analyses encompassing studies ZX008-1503 and ZX008-1601 cohort B. The Package Leaflet is updated accordingly.
C.I.4: Update of section 5.1 of the SmPC in order to update clinical efficacy information for
Dravet syndrome based on final results from study ZX008-1503 listed as a category 3 study in the RMP. This is an open-label extension trial to assess the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet syndrome.

C.I.4: Update of section 5.1 of the SmPC in order to update clinical efficacy information for Lennox-Gastaut syndrome based on final results from study ZX008-1601 Part 1 cohort B and interim results for study ZX008-1601 Part 2 cohort B. Study 1601 Part 1 was an international, randomized, double-blind, parallel-group, placebo-controlled study in subjects with LGS 2 to 35 years of age, while study 1601 Part 2 is a long-term, open-label, flexible-dose extension for subjects who completed study 1601 Part 1. The RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the Product Information, including to section 4.2 of the SmPC.”

Request for Supplementary Information adopted on 21.03.2024.

Idefirix - Imlifidase -
EMEA/H/C/004849/II/0019, Orphan
Hansa Biopharma AB, Rapporteur: Martina Weise, PRAC Rapporteur: Bianca Mulder,
“Update of section 5.1 of the SmPC in order to include the description of the final results from PAES study 17-HMedIdeS-14 listed as a specific obligation in the Annex II (SOB/002); this is a prospective, observational long-term follow-up study of patients treated with imlifidase (IdeS) prior to kidney transplantation. The primary objective of this trial was to evaluate graft survival in patients who have undergone kidney transplantation after imlifidase administration in earlier trials and relates to both safety and efficacy. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to update section E of Annex II and to implement editorial changes to sections 4.4, 4.6 and 9 of the SmPC. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3.”

Request for Supplementary Information adopted with a specific timetable.
Ilumetri - Tildrakizumab -
EMEA/H/C/004514/II/0054
Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski, "Update of section 5.1 of the SmPC in order to update clinical and safety information based on long-term results from the extension periods of the pivotal clinical studies MK-3222-010 (A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)) and MK-3222-011 (A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis). The RMP version 1.4 has also been submitted." Request for Supplementary Information adopted on 07.03.2024.

IMVANEX - Smallpox vaccine (live modified vaccinia virus Ankara) -
EMEA/H/C/002596/II/0100
Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Update of section 5.1 of the SmPC in order to add vaccine effectiveness data, and the removal of the two open specific obligations (POX-MVA-039 (SOB02) and SEMVAc (SOB03)), based on the IMVANEX vaccine effectiveness data in real-world use during the 2022 monkeypox outbreak. Consequently, the MAH proposes a switch from exceptional marketing authorisation to full marketing authorisation. The Annex II and Package Leaflet are updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 21.03.2024.

Isturisa - Osilodrostat -
EMEA/H/C/004821/II/0017/G, Orphan
Positive Opinion adopted by consensus on 07.03.2024.
Recordati Rare Diseases, Rapporteur: Kristina Dunder, PRAC Rapporteur: Maria del Pilar Rayon, "Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study LINC4 (study CLCI699C2302 - A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s disease).
- Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study LINC3 (study CLCI699C2301 - A Phase III, multi-center, double-blind, randomized withdrawal study of LC699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LC699 for the treatment of patients with Cushing’s disease).
The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce some minor editorial changes to the PI.”
Opinion adopted on 07.03.2024.

Juluca - Dolutegravir / Rilpivirine - EMEA/H/C/004427/II/0057/G
ViiV Healthcare B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Nathalie Gault, "Grouped application comprising two type II variations as follows:
C.I.13: Submission of the final report from study 201636 (SWORD 1) listed as a category 3 study in the RMP. This is a phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed.
C.I.13: Submission of the final report from study 201637 (SWORD 2) listed as a category 3 study in the RMP. This is a phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety,
and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. The RMP version 7.0 has also been submitted. “Request for Supplementary Information adopted on 07.03.2024.

**Jyseleca - Filgotinib -**
**EMEA/H/C/005113/II/0031/G**
Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Petar Mas, "Grouped application comprising two variations as follows: Type II (C.I.4): Update of sections 4.8 and 5.1 of the SmPC to update the safety mean duration exposure and efficacy information based on final results (up to Week 432) from study GLPG0634-CL-205 (DARWIN 3) listed as a category 3 study in the RMP (MEA/009); this is a phase II, open-label, long-term follow-up safety and efficacy study to evaluate the long-term safety and tolerability of filgotinib for the treatment of Rheumatoid Arthritis in patients who received treatment in their parent studies. The RMP version 6.1 has also been submitted. Type IA (A.6): To change the ATC code for Janus-associated kinase (JAK) inhibitor from L04AA45 filgotinib to L04AF04 filgotinib.” Request for Supplementary Information adopted on 07.03.2024.

**Kuvan - Sapropterin -**
**EMEA/H/C/000943/II/0078**
BioMarin International Limited, Rapporteur: Jayne Crowe, PRAC Rapporteur: Eamon O Murchu, “Submission of the final report from study KOGNITO, listed as a category 3 study in the RMP. This is a Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan) for 7 Years. The RMP version 16.0 has also been submitted.” Request for Supplementary Information adopted on 07.03.2024, 11.01.2024, 28.09.2023.

**Ondexxya - Andexanet alfa -**
**EMEA/H/C/004108/II/0044**
AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and efficacy

See 9.1

Request for supplementary information adopted with a specific timetable.
information based on the final results from study 18-513 (ANNEXA-I), listed as a specific obligation in the Annex II; this is a phase 4 randomised controlled trial to investigate the efficacy and safety of andexanet alfa versus usual care in patients with acute intracranial haemorrhage taking apixaban, rivaroxaban or edoxaban. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation. The Annex II and Package Leaflet are updated accordingly. The updated RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the latest QRD template version 10.3.”
Request for Supplementary Information adopted on 21.03.2024.

Onglyza - Saxagliptin - EMEA/H/C/001039/II/0057
AstraZeneca AB, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Bianca Mulder, "Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to include safety, efficacy and pharmacokinetic information in paediatric patients with Type 2 diabetes mellitus (T2DM) aged 10 to <18 years of age based on interim results from study D1680C00019 (T2NOW). This is a 26-week, multicentre, randomised, placebo-controlled, double-blind, parallel group, Phase III trial with a 26-week safety extension period evaluating the safety and efficacy of dapagliflozin (5 and 10 mg), and separately, saxagliptin (2.5 and 5 mg) in paediatric patients with T2DM who were between 10 and below 18 years of age. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity bring the PI in line with the latest QRD template, to introduce editorial changes and to update the contact details of the local representative in the Netherlands in the Package Leaflet. The RMP version 17.1 was agreed during the procedure.”
Opinion adopted on 29.02.2024.
"Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study LIBRETTO-431 (JZJC) listed as a specific obligation in the Annex II (SOB/002); this is a randomized Phase 3 study comparing selpercatinib to platinum-based and pemetrexed therapy with or without pembrolizumab in patients with locally advanced or metastatic, RET-fusion-positive NSCLC. The Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. In addition, the MAH took the opportunity to update Annex II."
Request for Supplementary Information adopted on 07.03.2024.

RoActemra - Tocilizumab - EMEA/H/C/000955/II/0121
Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Submission of the final report from study ZUMA-8 (PAM). This is a phase 1 multicenter study evaluating the safety and tolerability of KTE-X19 in adult subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The RMP version 29.0 has also been submitted." Request for Supplementary Information adopted on 07.03.2024.

Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0015
Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.6 of the SmPC in order to update information on pregnancy based on a comprehensive analysis of the results from the drug pregnancy registry cohort (PDC study GV44373), listed as a category 3 PASS in the RMP, as well as data from clinical studies and post-marketing surveillance. The RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the list of local representatives in the Package Leaflet."
Request for Supplementary Information adopted on 07.03.2024.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0096
Positive Opinion adopted by consensus on 07.03.2024.
AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC
Rapporteur: Jean-Michel Dogné, "Update of sections 4.8 and 5.1 of the SmPC based on final results from study D7220C00001; this is a phase 2/3 partially double-blinded, randomised, multinational, active-controlled study in both previously vaccinated and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of SARS-CoV-2. The RMP version 8 succession number 3 was submitted to consolidate the updates made in RMP as part of two parallel procedures (EMEA/H/C/005675/II/0096 and EMEA/H/C/005675/II/0097). In addition, the MAH took the opportunity to update in the EU-RMP the submission milestone date for study D8111R00010."
Opinion adopted on 07.03.2024.
Request for Supplementary Information adopted on 08.02.2024.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -
EMEA/H/C/005675/II/0097
AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC
Rapporteur: Jean-Michel Dogné, "Submission of the final report from study D8110C00001 listed as a category 3 study in the RMP (SOB/020). This is a phase III, randomised, placebo-controlled study of AZD1222 (Vaxzevria) conducted in the US, Peru and Chile. The purpose of the final CSR addendum is to provide long-term safety data through to study completion and include the second year of follow-up post-first dose and final day 730 visit. The RMP version 8 succession number 3 was submitted to consolidate the updates made in RMP as part of two parallel procedures (EMEA/H/C/005675/II/0096 and EMEA/H/C/005675/II/0097). In addition, the MAH took the opportunity to update in the EU-RMP the submission milestone date for study D8111R00010."
Opinion adopted on 07.03.2024.
Request for Supplementary Information adopted on 08.02.2024.

Vyvgart - Efgartigimod alfa -
EMEA/H/C/005849/II/0014, Orphan
Argenx, Rapporteur: Thalia Marie Estrup Blicher,
Request for supplementary information adopted with a specific timetable.
PRAC Rapporteur: Rhea Fitzgerald, "Update of section 4.4 of the SmPC in order to amend an existing warning on infusion reactions and hypersensitivity reactions, and update of section 5.1 of the SmPC to update the mechanism of action of efgartigimod in relation to albumin; based on final results from study ARGX-113-1705 listed a category 3 study in the RMP. This is a long-term, single-arm, open-label, multicenter, phase 3 follow-on study of ARGX-113-1704 to evaluate the safety and tolerability of ARGX-113 in patients with myasthenia gravis having generalized muscle weakness. The RMP version 2.2 has also been submitted."
Request for Supplementary Information adopted on 07.03.2024, 11.01.2024.

**Xevudy - Sotrovimab - EMEA/H/C/005676/II/0026**

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Liana Martirosyan, "To update sections 4.2, 4.8 and 5.2 of the SmPC in order to update information on paediatric population based on final results from study COMET-PACE (215226), a category 3 study in the RMP; this is an open-label, non-comparator, multicentre study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in paediatric participants with mild to moderate COVID-19 at high risk of disease progression. The RMP version 1.1 has also been updated."
Opinion adopted on 07.03.2024.
Request for Supplementary Information adopted on 08.02.2024.

**ZTALMY - Ganaxolone - EMEA/H/C/005825/II/0005, Orphan**

Marinus Pharmaceuticals Emerald Limited, Rapporteur: Peter Mol, PRAC Rapporteur: Adam Przybyłkowski, "Update of section 4.2 of the SmPC in order to update dosing instructions in severe hepatic impairment based on data from phase I study 1042-IHF-1001. The RMP version 1.3 has also been submitted."
Request for Supplementary Information adopted on 21.03.2024.

**WS2631 Kisplyx-EMEA/H/C/004224/WS2631/0059**

Positive Opinion adopted by consensus on 07.03.2024.

Request for supplementary information adopted with a specific timetable.
**Lenvima**
**EMEA/H/C/003727/WS2631/0054**
Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, Lead PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC for Kisplyx and sections 4.8 and 5.1 of the SmPC for Lenvima, in order to reflect the results of two completed paediatric clinical studies E7080-G000-216 and E7080-G000-231. Study 231 is a Phase 2, open-label, multicenter basket study to evaluate the antitumor activity and safety of Lenvatinib in children, adolescents, and young adults with relapsed or refractory solid malignancies. Study 216 is a Phase 1/2, multicenter, open-label, single arm study of lenvatinib in combination with everolimus in pediatric subjects (and young adults aged ≤21 years) with relapsed or refractory malignant solid tumors. The Package Leaflet for Kisplyx is updated accordingly. The RMP version 15.3 has also been submitted.”
Opinion adopted on 21.03.2024.
Request for Supplementary Information adopted on 22.02.2024.

**Dengue Tetravalent Vaccine (Live, Attenuated) Takeda**
**EMEA/H/W/005362/WS2593/0012**
Qdenga-
**EMEA/H/C/005155/WS2593/0013**
Takeda GmbH, Lead Rapporteur: Sol Ruiz, Lead PRAC Rapporteur: Liana Martirosyan, “Update of section 4.5 of the SmPC in order to add co-administration information with HPV vaccine based on final results from study DEN-308 listed as a category 3 study in the RMP (MEA003/MEA004); this is a Phase 3, open-label, randomized trial to investigate the immunogenicity and safety of the co-administration of a subcutaneous dengue tetravalent vaccine (live, attenuated) (TDV) and an intramuscular recombinant 9-valent human papillomavirus (9vHPV) vaccine in subjects aged ≥9 to <15 years in an endemic country for dengue; the Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes and to update the text on PSUR submissions in Annex II for Dengue tetravalent vaccine.”
Request for Supplementary Information adopted with a specific timetable.
### B.5.4. PRAC assessed procedures

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enbrel - Etanercept - EMEA/H/C/000262/II/0254</strong></td>
<td></td>
</tr>
<tr>
<td>Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “Update of section 4.8 of the SmPC in order to update the frequency of Adverse Drug Reaction (ADR) ‘Glomerulonephritis’ from ‘Not Known’ to ‘Rare’ following PSUSA/00010795/202302 procedure, based on available evidence from clinical trials, literature, and post-marketing data. The Package Leaflet is updated accordingly.” Request for Supplementary Information adopted on 07.03.2024.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Positive Opinion adopted by consensus on 07.03.2024.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Entyvio - Vedolizumab - EMEA/H/C/002782/II/0081</strong></td>
<td></td>
</tr>
<tr>
<td>Takeda Pharma A/S, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, “Update of section 4.6 of the SmPC in order to update information on pregnancy based on final results from study Vedolizumab-5001 (OTIS Entyvio Pregnancy Exposure Registry); this is a non-interventional study to monitor planned and unplanned pregnancies in female patients with ulcerative colitis or Crohn’s disease. In addition, the MAH took the opportunity to introduce minor changes and corrections to the PI and bring it in line with the latest QRD template.” Opinion adopted on 07.03.2024. Request for Supplementary Information adopted on 08.02.2024.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HyQvia - Human normal immunoglobulin - EMEA/H/C/002491/II/0096</strong></td>
<td></td>
</tr>
<tr>
<td>Baxalta Innovations GmbH, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Update of sections 4.8 and 5.1 of the SmPC in order to update long-term safety information based on final results from studies 161406 &quot;Non-Interventional Post-</td>
<td></td>
</tr>
</tbody>
</table>
Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)” listed as category 3 a study in the RMP and 161302 “Non-Interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects Treated with HyQvia”. Both studies were non-interventional, prospective, uncontrolled, multicenter, open-label, post-authorisation studies. The RMP version 15.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3, to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI.” Request for Supplementary Information adopted on 07.03.2024.

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Intuniv - Guanfacine - EMEA/H/C/003759/II/0033/G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takeda Pharmaceuticals International AG Ireland Branch, PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “Submission of the final reports from the Drug Utilisation Study of Intuniv (guanfacine extended release) in European countries: a prescriber survey (EUPAS18739) and a retrospective database study (EUPAS18735), listed as category 3 studies in the RMP. The RMP version 4.0 has also been submitted.” Request for Supplementary Information adopted on 07.03.2024, 28.09.2023.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Nplate - Romiplostim - EMEA/H/C/000942/II/0091</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen Europe B.V., PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “Submission of an updated RMP version 22 in order to include the latest safety information collected until 31 July 2023 (data lock point). The main change consists of removing the neutralizing antibodies that cross-react with endogeneous thrombopoietin (eTPO).” Opinion adopted on 07.03.2024.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>NUVAXOVID - Covid-19 Vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0060</th>
</tr>
</thead>
<tbody>
<tr>
<td>Request for supplementary information adopted with a specific timetable.</td>
<td>Positive Opinion adopted by consensus on 07.03.2024.</td>
</tr>
<tr>
<td><strong>Novavax CZ, a.s., PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, &quot;Submission of an updated RMP version 4.2 after approval of adapted COVID-19 vaccine by new strain, Omicron XBB.1.5.&quot;</strong></td>
<td><strong>Request for Supplementary Information adopted on 07.03.2024.</strong></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>PRAC Led</strong></td>
<td><strong>Request for supplementary information adopted with a specific timetable.</strong></td>
</tr>
</tbody>
</table>
| **SARCLISA - Isatuximab -**  
**EMEA/H/C/004977/II/0027** | **Sanofi Winthrop Industrie, PRAC Rapporteur:**  
Monica Martinez Redondo, PRAC-CHMP liaison: Carolina Prieto Fernandez, "Update of section 4.8 of the SmPC in order to add ‘Thrombocytopenia’ and ‘Anaemia’ to the list of adverse drug reactions (ADRs) and to amend the frequency of all remaining ADRs with their appropriate frequencies, following PRAC request in the outcome of the PSUSA procedure PSUSA/00010851/202303.”  
**Request for Supplementary Information adopted on 07.03.2024.** |
| **TRODELVY - Sacituzumab govitecan -**  
**EMEA/H/C/005182/II/0031** | **Gilead Sciences Ireland UC, PRAC Rapporteur:**  
Bianca Mulder, PRAC-CHMP liaison: Peter Mol, "Submission of an updated RMP version 3.1 in order to propose the removal of safety concerns.”  
**Request for Supplementary Information adopted on 07.03.2024.** |
| **Vedrop - Tocofersolan -**  
**EMEA/H/C/000920/II/0047** | **Recordati Rare Diseases, PRAC Rapporteur:**  
Melinda Palfi, PRAC-CHMP liaison: Beata Maria Jakline Ullrich, “Submission of an updated RMP version 10.2 in order to remove all important potential risks and missing information from the list of safety concerns, to align with the new RMP format according to Good Pharmacovigilance Practices Module V Revision 2 and to remove one closed post-authorisation safety study of category 2 (Recordati Rare Diseases’ Vedrop registry) from the pharmacovigilance plan.”  
**Opinion adopted on 07.03.2024.**  
**Request for Supplementary Information adopted** |
B.5.5. CHMP-CAT assessed procedures

**Breyanzi - Lisocabtagene maraleucel** / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0037/G, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini
Request for Supplementary Information adopted on 15.03.2024.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS2614</strong> Cegfila- Pelmeg- Mundipharma Corporation (Ireland) Limited, Lead Rapporteur: Karin Janssen van Doorn</td>
<td>Positive Opinion adopted by consensus on 14.03.2024. Request for Supplementary Information adopted</td>
</tr>
</tbody>
</table>
WS2635
Hexacima-
EMEA/H/C/002702/WS2635/0155
Hexyon-
EMEA/H/C/002796/WS2635/0159
MenQuadfi-
EMEA/H/C/005084/WS2635/0032
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 21.03.2024.

Positive Opinion adopted by consensus on 21.03.2024.

WS2644/G
Entresto-
Neparvis-
Novartis Europharm Limited, Lead Rapporteur:
Patrick Vrijlandt
Opinion adopted on 14.03.2024.

Positive Opinion adopted by consensus on 14.03.2024.

WS2661
Mirapexin-
EMEA/H/C/000134/WS2661/0108
Sifrol-EMEA/H/C/000133/WS2661/0099
Boehringer Ingelheim International GmbH, Lead Rapporteur: Thalia Marie Estrup Blicher
Request for Supplementary Information adopted on 29.02.2024.

Request for supplementary information adopted with a specific timetable.

WS2666/G
Ongentys-
EMEA/H/C/002790/WS2666/0065/G
Ontilyv-
EMEA/H/C/005782/WS2666/0020/G
Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise
Opinion adopted on 21.03.2024.

Positive Opinion adopted by consensus on 21.03.2024.

B.5.9. Information on withdrawn type II variation / WS procedure

Brukinsa - Zanubrutinib -
EMEA/H/C/004978/II/0018
BeiGene Ireland Ltd, Rapporteur: Aaron Sosa Mejia, “Update of sections 4.2 and 4.5 of the SmPC in order to update information with regards to concomitant use of moderate CYP3A inducers based on final results from the drug-drug interaction study BGB-3111-112; this is a phase 1, open-label, fixed-sequence study to investigate the effect of the moderate CYP3A inducer rifabutin on the pharmacokinetics of zanubrutinib in healthy male subjects.”

The MAH withdrew the procedure on 11.03.2024.
Withdrawal request submitted on 11.03.2024.

<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA/H/C/Number</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kymriah - Tisagenlecleucel - EMEA/H/C/004090/II/0072, Orphan, ATMP</td>
<td>Novartis Europharm Limited, Rapporteur: Rune Kjeken</td>
<td>The MAH withdrew the procedure on 14.03.2024.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA/H/C/Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tocilizumab - EMEA/H/C/006196</td>
<td>treatment of rheumatoid arthritis (RA)</td>
<td></td>
</tr>
<tr>
<td>Datopotamab - EMEA/H/C/006547</td>
<td>Treatment of adult patients with inoperable or metastatic HR-positive / HER2-negative breast cancer with disease progression following chemotherapy in the metastatic setting</td>
<td></td>
</tr>
<tr>
<td>Datopotamab - EMEA/H/C/006081</td>
<td>treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)</td>
<td></td>
</tr>
<tr>
<td>Pegfilgrastim - EMEA/H/C/006407</td>
<td>treatment of neutropenia</td>
<td></td>
</tr>
<tr>
<td>Resminostat - EMEA/H/C/006259, Orphan</td>
<td>4Sc AG, treatment of patients with advanced stage mycosis fungoides (MF) and Sézary syndrome (SS)</td>
<td></td>
</tr>
<tr>
<td>Seladelpar lysine dihydrate - EMEA/H/C/004692, Orphan</td>
<td>CymaBay Ireland, Ltd, treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child-Pugh A) in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA</td>
<td></td>
</tr>
<tr>
<td>Nirogacestat - EMEA/H/C/006071, Orphan</td>
<td>Springworks Therapeutics Ireland Limited, treatment of desmoid tumours</td>
<td></td>
</tr>
<tr>
<td>Product Name</td>
<td>EMEA Number</td>
<td>Description</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Aflibercept - EMEA/H/C/006339</td>
<td>treatment of age-related macular degeneration (AMD), visual impairment and retinopathy of prematurity (ROP), treatment of age-related macular degeneration (AMD) and visual impairment</td>
<td></td>
</tr>
<tr>
<td>Resmetirom - EMEA/H/C/006220</td>
<td>for the treatment of adults with nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis</td>
<td></td>
</tr>
<tr>
<td>Aflibercept - EMEA/H/C/006551</td>
<td>treatment of age-related macular degeneration (AMD) and visual impairment, treatment of age-related macular degeneration (AMD), visual impairment and retinopathy of prematurity (ROP)</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab - EMEA/H/C/006444</td>
<td>for the treatment of Crohn’s disease and ulcerative colitis</td>
<td></td>
</tr>
</tbody>
</table>

**B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aqumeldi - Enalapril maleate - EMEA/H/C/005731/X/0001/G</td>
<td>Proveca Pharma Limited, Rapporteur: John Joseph Borg, PRAC Rapporteur: Mari Thorn, &quot;Extension application to add a new strength of 1 mg orodispersible tablet grouped with a type 1B variation (C.I.z) to correct the SmPC to remove the recommended dose of epinephrine from section 4.4.&quot;</td>
<td></td>
</tr>
<tr>
<td>BIMERVAX - SARS-CoV-2, variant XBB.1.16, spike protein, receptor binding domain fusion homodimer / Selvacovatein - EMEA/H/C/006058/X/0014/G</td>
<td>Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich</td>
<td></td>
</tr>
<tr>
<td>Uzpruvo - Ustekinumab - EMEA/H/C/006101/X/0001</td>
<td>STADA Arzneimittel AG, Rapporteur: Christian Gartner, PRAC Rapporteur: Rhea Fitzgerald, &quot;Extension application to introduce a new pharmaceutical form associated with a new strength (130 mg concentrate for solution for infusion) and a new route of administration (intravenous use). The RMP version 1.1 is</td>
<td></td>
</tr>
</tbody>
</table>
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

**Axitinib - EMEA/H/C/006206**
treatment of adult patients with advanced renal cell carcinoma (RCC)

**Erdafitinib - EMEA/H/C/006050**
treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC)
List of Questions adopted on 25.01.2024.

**Bimzelx - Bimekizumab - EMEA/H/C/005316/X/0021**
UCB Pharma S.A., Rapporteur: Finbarr Leacy,
PRAC Rapporteur: Liana Martirosyan, “Extension application to add a new strength of 320 mg (160 mg/ml) for bimekizumab solution for injection in pre-filled syringe or pre-filled pen, for subcutaneous (SC) administration.”
List of Questions adopted on 25.01.2024.

**Cresemba - Isavuconazole - EMEA/H/C/002734/X/0042/G, Orphan**
Basilea Pharmaceutica Deutschland GmbH, 
Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski, “Extension application to add a new strength of 40 mg hard capsule to be used in paediatric patients 6 years and older grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of paediatric patients aged 1 year and older for CRESEMBA 200 mg powder, based on final results from studies 9766-CL-0107 and 9766-CL-0046. Study 9766-CL-0046 is a Phase 1, open-label, multicenter study to evaluate the PK, safety and tolerability of intravenous and oral isavuconazonium sulfate in paediatric patients. This study was conducted in two sequential parts: Part 1 with three intravenous dosing cohorts, and Part 2 with two oral dosing cohorts. Study 9766-CL-0107 is a Phase 2, open-label, non-comparative, multicenter study to evaluate the safety and tolerability, efficacy, and PK of isavuconazole for the treatment of invasive aspergillosis or mucormycosis in paediatric patients aged 1 to < 18 years. As a consequence, sections 4.1, 4.2, 4.5, 4.8,
5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted.”
List of Questions adopted on 25.01.2024.

**Enzalutamide - EMEA/H/C/006299**
Treatment of prostate cancer

**Donanemab - EMEA/H/C/006024**
To slow disease progression in adult patients with Alzheimer’s disease (AD).

**Mektovi - Binimetinib - EMEA/H/C/004579/X/0029**
Pierre Fabre Medicament, Rapporteur: Janet Koenig, “Extension application to add a new strength of 45 mg (film-coated tablets).”
List of Questions adopted on 25.01.2024.

**Single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation - EMEA/H/C/006278**
Prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory syncytial virus (RSV)
List of Questions adopted on 09.11.2023.

**Nilotinib - EMEA/H/C/006315**
Treatment of Philadelphia chromosome positive chronic myelogenous leukaemia (CML)
List of Questions adopted on 09.11.2023.

**Ocrevus - Ocrelizumab - EMEA/H/C/004043/X/0039**
Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Gabriele Maurer, “Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (920 mg) and new route of administration (subcutaneous use).
The RMP (version 9.0) is updated in accordance.”
List of Questions adopted on 25.01.2024.

**Odronextamab - EMEA/H/C/006215, Orphan**
Regeneron Ireland Designated Activity Company, treatment of blood cancers (follicular lymphoma (FL) or diffuse large B cell lymphoma
Crovalimab - EMEA/H/C/006061
treatment of paroxysmal nocturnal haemoglobinuria
List of Questions adopted on 09.11.2023.

Pomalidomide - EMEA/H/C/006273
treatment of adult patients with multiple myeloma
List of Questions adopted on 25.01.2024.

Pomalidomide - EMEA/H/C/006314
treatment of multiple myeloma
List of Questions adopted on 25.01.2024.

Pomalidomide - EMEA/H/C/006294
treatment of adults with multiple myeloma
List of Questions adopted on 25.01.2024.

Rybelsus - Semaglutide -
EMEA/H/C/004953/X/0038
Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt,
"Extension application to introduce three new strengths of tablets (1.5 mg, 4 mg and 9 mg) for semaglutide."
List of Questions adopted on 22.02.2024.

Skyrizi - Risankizumab -
EMEA/H/C/004759/X/0043/G
AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Finbarr Leacy, PRAC Rapporteur: Liana Martirosyan, "Extension application to a new strength of 180 mg of risankizumab (solution for injection in cartridge) grouped with a type II variation extension of indication (C.I.6.a) to include treatment of adult patients with moderately to severely active ulcerative colitis, for SKYRIZI, based on final results from studies M16-067 substudy 2: a phase 2b/3 multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis, and M16-066 substudy 1: a multicenter, randomized, double-blind, placebo controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis, as well as DDI study M19-974. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC for the Skyrizi 600 mg
concentrate for solution for infusion, and sections 1, 2, 4.1, 4.2, 4.8, 5.1, 5.2, 5.3, 6.5 and 6.6 of the SmPC for the Skyrizi 360 mg solution for injection in cartridge are updated. The Annex II, Labelling and Package Leaflets are updated in accordance. Version 5.0 of the RMP has also been submitted.”
List of Questions adopted on 25.01.2024.

Sotatercept - EMEA/H/C/005647, Orphan
Merck Sharp & Dohme B.V., treatment of pulmonary arterial hypertension in adults
List of Questions adopted on 23.01.2024.

Macitentan / Tadalafil - EMEA/H/C/005001
treatment of pulmonary arterial hypertension (PAH) in adults patients
List of Questions adopted on 09.11.2023.

B.6.4. Annual Re-assessments: timetables for adoption

Ebvallo - Tabelecleucel -
EMEA/H/C/004577/S/0008, Orphan, ATMP
Pierre Fabre Medicament, Rapporteur: Egbert Flory, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Amelia Cupelli

ELZONRIS - Tagraxofusp -
EMEA/H/C/005031/S/0025, Orphan
Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Bianca Mulder

Obizur - Susoctocog alfa -
EMEA/H/C/002792/S/0056
Baxalta Innovations GmbH, Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Gabriele Maurer

Tecovirimat SIGA - Tecovirimat -
EMEA/H/C/005248/S/0010
SIGA Technologies Netherlands B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Martin Huber

Voraxaze - Glucarpidase -
EMEA/H/C/005467/S/0025, Orphan
SERB S.A.S., Rapporteur: Petr Vrbata, PRAC Rapporteur: Martin Huber
### B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Common Name</th>
<th>EMA Reference</th>
<th>Type of Authorization</th>
<th>Manufacturer</th>
<th>Rapporteur 1</th>
<th>Co-Rapporteur</th>
<th>PRAC Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinpeygo - Budesonide -</td>
<td>EMEA/H/C/005653/R/0010, Orphan</td>
<td>STADA Arzneimittel AG</td>
<td>Rapporteur: Christian Gartner, PRAC</td>
<td>Rapporteur: Marie Louise Schougaard Christiansen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RINVOQ - Upadacitinib -</td>
<td>EMEA/H/C/004760/R/0051</td>
<td>AbbVie Deutschland GmbH &amp; Co. KG</td>
<td>Rapporteur: Kristina Dunder, Co-Rapporteur: Outi Mäki-Ikola, PRAC</td>
<td>Rapporteur: Petar Mas</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

### B.6.7. Type II Variations scope of the Variations: Extension of indication

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Common Name</th>
<th>EMA Reference</th>
<th>Type of Authorization</th>
<th>Manufacturer</th>
<th>Rapporteur</th>
<th>PRAC Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLINCYTO - Blinatumomab -</td>
<td>EMEA/H/C/003731/II/0056, Orphan</td>
<td>Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC</td>
<td>Rapporteur: Jana Lukacisinova,</td>
<td>&quot;Extension of indication to include treatment as part of consolidation therapy for the treatment of patients with Philadelphia chromosome</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
negative CD19 positive B-cell precursor ALL for BLINCYTO. The proposed indication is supported by efficacy data from Studies E1910, 20120215, and AALL1331, safety data for Studies E1910, 20120215, AALL1331, MT103-202, and MT103-203, and Pharmacokinetic data for Studies 20120215, AALL1331, MT103-202, MT103-203, and 20190360. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted.”

**Dupixent - Dupilumab - EMEA/H/C/004390/II/0083**

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, “Extension of indication to include treatment of moderate to severe chronic spontaneous urticaria in adults and adolescents 12 years and older, who are symptomatic despite treatment with H1 antihistamines and who are intolerant to or inadequately controlled by anti-IgE therapy for Dupixent, based on the results from studies EFC16461 (CUPID) study B (pivotal) and study A (supportive); EFC16461 Study B was a 24-week, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of dupilumab in adult and adolescent participants with CSU who remained symptomatic despite the use of H1-antihistamine and who were intolerant or incomplete responders to omalizumab and EFC16461 Study A was a 24-week, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of dupilumab in participants with CSU who remained symptomatic despite the use of H1-antihistamine and who were naïve to omalizumab. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.0 of the RMP has also been submitted.”

**Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0017**

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ulla Wändel Liminga, “Extension of indication to include treatment of
paediatric patients from 2 to less than 12 years old, weighing at least 10kg, who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19 for Ronapreve, based on final results from study COV-2067; this was a seamless, adaptive, Phase 3, randomized, double-blinded, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of casirivimab+imdevimab combination therapy in paediatric and adult outpatients with mild to moderate COVID-19. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

**RYBREVANT - Amivantamab -**

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer, "Extension of indication to include amivantamab in combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (EGFRm NSCLC), based on results from study 73841937NSC3003 (MARIPOSA). This is a randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC. The primary objective of the MARIPOSA study was to assess the efficacy of the combination of amivantamab and lazertinib (Arm A), compared with osimertinib (Arm B), as measured by PFS assessed by BICR in adult participants with EGFRm NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2, 6.6 and 9 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.3 of the EU RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
**Sialanar - Glycopyrronium**  
**EMEA/H/C/003883/II/0029**

Proveca Pharma Limited, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Zane Neikena,  
"Extension of indication to include treatment of children aged from 2 years and older for SIALANAR, based on the interim results from study PRO/GLY/005. This is a retrospective analysis of real world data from children aged under 3 years treated with glycopyrronium for severe drooling. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated. The Package Leaflet is updated in accordance.  
Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. As part of the application the MAH is requesting a 1-year extension of the market protection.”  
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Synjardy - Empagliflozin / Metformin**  
**EMEA/H/C/003770/II/0078**

Boehringer Ingelheim International GmbH,  
Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Maria del Pilar Rayon,  
"Extension of indication to include the treatment of children aged 10 years and above with type 2 diabetes for Synjardy, based on the final results from study 1218-0091 (DINAMO) - A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 16.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”

**Tevimbra - Tislelizumab**  
**EMEA/H/C/005919/II/0006**

Beigene Ireland Limited, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder,  
"Extension of indication to include in
combination with platinum and fluoropyrimidine-based chemotherapy the first-line treatment of adult patients with human epidermal growth factor receptor-2 (HER-2)-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma for TEVIMBRA, based on results from the phase 3 study BGB-A317-305 (study 305); this is a global, randomized, double-blind, placebo-controlled study at the approved registrational dosing regimen for Tevimbra (200 mg administered IV Q3W), in combination with platinum and fluoropyrimidine-based chemotherapy, in adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information.”

**Yselty - Linzagolix choline -**

EMEA/H/C/005442/II/0013

Theramex Ireland Limited, Rapporteur: Finbarr Leacy, Co-Rapporteur: Margareta Bego, PRAC Rapporteur: Martin Huber, “Extension of indication to include treatment of endometriosis-associated pain in adult women of reproductive age for YSELTY, based on final results from studies Edelweiss 3 (18-OBE2109-003) and Edelweiss 6 (19-OBE2109-006) as well as additional supporting studies. Edelweiss 3 is a pivotal phase 3, randomised, double-blind, placebo-controlled, safety and efficacy study to evaluate linzagolix with add-back therapy as a therapy for pain associated with endometriosis, while Edelweiss 6 is an open-label extension study including patients who completed Edelweiss 3 pivotal study regardless of their previous treatment assignment and met the eligibility criteria. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. As part of the application, the MAH is requesting a 1-year extension of the market protection.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Atosiban SUN – Atosiban -
EMA/VR/0000167976
Sun Pharmaceutical Industries (Europe) B.V., Rapporteur: John Joseph Borg

AREXVY - Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E -
EMEA/H/C/006054/II/0009/G
GlaxoSmithkline Biologicals S.A., Rapporteur: Patrick Vrijlandt

BUCCOLAM - Midazolam -
EMEA/H/C/002267/II/0062/G
Neuraxpharm Pharmaceuticals S.L., Rapporteur: Peter Mol

Buvidal - Buprenorphine -
EMEA/H/C/004651/II/0025
Camurus AB, Rapporteur: Finbarr Leacy

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -
EMEA/H/C/005735/II/0212/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

DuoTrav - Travoprost / Timolol -
EMEA/H/C/000665/II/0068/G
Novartis Europharm Limited, Rapporteur: Maria Concepcion Prieto Yerro

Ervebo - Recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) -
EMEA/H/C/004554/II/0035
Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke

Evenity - Romosozumab -
EMEA/H/C/004465/II/0023
UCB Pharma S.A., Rapporteur: Kristina Dunder

Evenity - Romosozumab -
EMEA/H/C/004465/II/0024
UCB Pharma S.A., Rapporteur: Kristina Dunder

Gilenya - Fingolimod -
EMEA/H/C/002202/II/0088
Novartis Europharm Limited, Rapporteur:
Alexandre Moreau

**LUTATHERA - Lutetium (177Lu)**
oxodotreotide -  
*EMEA/H/C/004123/II/0048, Orphan*  
Advanced Accelerator Applications, Rapporteur: Janet Koenig

**Mircera - Methoxy polyethylene glycol-epoetin beta**  
*EMEA/H/C/000739/II/0099/G*  
Roche Registration GmbH, Rapporteur: Maria Concepcion Prieto Yerro

**Nucala - Mepolizumab**  
*EMEA/H/C/003860/II/0066/G*  
GlaxoSmithKline Trading Services Limited, Rapporteur: Finbarr Leacy

**NUVAXOVID - Covid-19 Vaccine (recombinant, adjuvanted)**  
*EMEA/H/C/005808/II/0063/G*  
Novavax CZ, a.s., Rapporteur: Patrick Vrijlandt

**Orencia - Abatacept**  
*EMEA/H/C/000701/II/0166/G*  
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Outi Mäki-Ikola

**OXERVATE - Cenegermin**  
*EMEA/H/C/004209/II/0059, Orphan*  
Dompe farmaceutici S.p.A., Rapporteur: Maria Concepcion Prieto Yerro

**Ozempic - Semaglutide**  
*EMEA/H/C/004174/II/0044/G*  
Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt

**Rotarix - Rotavirus vaccine (live, oral)**  
*EMEA/H/C/000639/II/0133/G*  
GlaxoSmithKline Biologicals S.A., Rapporteur: Christophe Focke

**SomaKit TOC - Edotreotide**  
*EMEA/H/C/004140/II/0028, Orphan*  
Advanced Accelerator Applications, Rapporteur: Maria Concepcion Prieto Yerro

**Spikevax - COVID-19 mRNA vaccine (nucleoside-modified)**  
*EMEA/H/C/005791/II/0123/G*  
Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus

**Spikevax - COVID-19 mRNA vaccine (nucleoside-modified)**
<table>
<thead>
<tr>
<th>EMEA/H/C/005791/II/0124/G</th>
<th>Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stimufend - Pegfilgrastim - EMEA/H/C/004780/II/0007</td>
<td>Fresenius Kabi Deutschland GmbH, Rapporteur: Christian Gartner</td>
</tr>
<tr>
<td>Travatan - Travoprost - EMEA/H/C/000390/II/0071/G</td>
<td>Novartis Europharm Limited, Rapporteur: Maria Concepcion Prieto Yerro</td>
</tr>
<tr>
<td>TRODELVY - Sacituzumab govitecan - EMEA/H/C/005182/II/0032</td>
<td>Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>TRODELVY - Sacituzumab govitecan - EMEA/H/C/005182/II/0033</td>
<td>Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Vazkepa - Icosapent ethyl - EMEA/H/C/005398/II/0023/G</td>
<td>Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise</td>
</tr>
<tr>
<td>Vyvgart - Efgartimod alfa - EMEA/H/C/005849/II/0017, Orphan</td>
<td>Argenx, Rapporteur: Thalia Marie Estrup Blicher</td>
</tr>
<tr>
<td>Zyclara-EMEA/H/C/002387/WS2550/0031</td>
<td>AstraZeneca AB, Lead Rapporteur: Finbarr Leacy</td>
</tr>
</tbody>
</table>
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

**Biktarvy - Bictegravir / Emtricitabine / Tenofovir alafenamide -**
EMEA/H/C/004449/II/0059
Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, "Update of sections 4.4, 4.5, 4.6, 5.1 and 5.2 of the SmPC in order to update information on pregnancy and update the dosing recommendations with polyvalent caution-containing products for pregnant patients based on final results from GS-US-380-5310; A Phase 1b, Open-label study to Evaluate the Pharmacokinetics (PK), Safety and Efficacy of B/F/TAF in HIV-1 infected, Virologically Suppressed, Pregnant Women in their Second and Third Trimesters; study GS-US-380-3909 and the Antiretroviral Pregnancy Registry. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes."

**Cetrotide - Cetrorelix -**
EMEA/H/C/000233/II/0091
Merck Europe B.V., Rapporteur: Martina Weise, "Type II C.I.4 To update section 6.6 of the SmPC to amend the administered dose of cetrorelix from 'dose of at least 0.23 mg' to 'dose of 0.21 mg' based on the representative dose study conducted to evaluate the administered dose after reconstitution."

**Erleada - Apalutamide -**
EMEA/H/C/004452/II/0036
Janssen-Cilag International N.V., Rapporteur: Carolina Prieto Fernandez, "- to update the method of administration for Erleada 60 mg film-coated tablets provided in the SmPC section 4.2 (and related section of the PL) to allow patients to take tablets with non-fizzy beverage or soft food, or by a nasogastric
feeding tube; hence, aligning the vehicles for administration between the two Erleada strengths (i.e. 60 mg and 240 mg).

The MAH took the opportunity to introduce the following editorial changes:
- Irish country code has been added in the contact information of the local representative;
- New link for reporting of adverse events in section 4.8 of SmPC and section 4 of PL has been provided.”

**Keytruda - Pembrolizumab -**  
**EMEA/H/C/003820/II/0152**  
Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, "Update of section 5.1 of the SmPC in order to update efficacy information based on interim results from study KEYNOTE-564; this is a phase 3, randomized, double-blind, placebo-controlled clinical trial of pembrolizumab as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy.”

**Kisqali - Ribociclib -**  
**EMEA/H/C/004213/II/0049**  
Novartis Europharm Limited, Rapporteur: Filip Josephson, "Update of sections 4.2 and 4.4 of the SmPC in order to update the ECG monitoring recommendations in patients with advanced or metastatic breast cancer (aBC) treated with ribociclib based on the continuing and comprehensive assessments of QT/QTcF effects in patients with cancer from studies A2301 (MONALEESA-2), E2301 (MONALEESA-7) and F2301 (MONALEESA-3). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes.”

**NUVAXOVID - Covid-19 Vaccine (recombinant, adjuvanted) -**  
**EMEA/H/C/005808/II/0066**  
Novavax CZ, a.s., Rapporteur: Patrick Vrijlandt, "Submission of the final report from clinical study 2019nCoV-101 Part 2 listed as a category 3 study in the RMP (MEA 010.2). This is a 2-part, phase 1/2, randomized, observer-blinded study to evaluate the safety and immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with or without Matrix-M adjuvant in healthy participants.”
Oncaspar - Pegasparagase -
EMEA/H/C/003789/II/0053/G
Les Laboratoires Servier, Rapporteur: Alexandre Moreau, "A grouped application comprised of a Type II variation and a Type IB variation, as follows:
- Type II (C.I.4): Update of sections 4.4 and 4.8 of the SmPC in order to add 'Hepatic veno-occlusive disease (VOD)' as a warning and new safety risk, following an internal signal evaluation. The Package Leaflet is updated accordingly.
- Type IB (C.I.3.z): Update of sections 4.4 and 4.8 of the SmPC in order to add 'Antithrombin III decreased' to the list of adverse drug reactions with frequency 'Very common' and to update the frequency of 'Neutrophil count decreased' from 'Not known' to 'Very common', following the outcome of the PAM procedure P46/008. The Package Leaflet is updated accordingly."

Onivyde pegylated liposomal - Irinotecan hydrochloride trihydrate -
EMEA/H/C/004125/II/0035, Orphan
Les Laboratoires Servier, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add "Interstitial lung disease (including pneumonitis)" to the list of adverse drug reactions (ADRs) with frequency "Not known" based on post-marketing data and literature. The Package Leaflet is updated accordingly."

Opfolda - Miglustat -
EMEA/H/C/005695/II/0010/G
Amicus Therapeutics Europe Limited, Rapporteur: Patrick Vrijlandt, "A grouped application comprised of two Type II Variations, as follows:
C.I.4: Update of section 5.2 of the SmPC in order to update drug metabolism information based on the final report of the in vitro transporter study 8496647 as well as the population PK study AMC0206. Study 8496647 was for the evaluation of miglustat as a substrate and inhibitor of a panel of human drug transporters.
C.I.4: Update of sections 4.6 and 5.3 of the SmPC in order to update reproductive and developmental toxicology information based on
reassessment of non-clinical data.
In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information.”

**Paxlovid - Nirmatrelvir / Ritonavir - EMEA/H/C/005973/II/0052/G**
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “A grouped application comprised of 2 Type II Variations, as follows:
C.I.4: Update of section 4.5 of the SmPC in order to include more detailed dosing information within the clinical comments for the drug-drug interactions (DDIs) related to venetoclax, apixaban, saxagliptin and cariprazine and to remove the reference to the dabigatran SmPC in the dabigatran DDI clinical comments.
C.I.4: Update of section 5.2 of the SmPC in order to include additional information related to the rosuvastatin DDI, based on the final results from study C4671052; this is a phase 1, randomized, fixed sequence, multiple dose, open-label study to estimate the effect of nirmatrelvir/ritonavir on rosuvastatin pharmacokinetics in healthy adult participants.”

**Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0030**
Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on ‘Slipped Capital Femoral Epiphysis/ Slipped Upper Femoral Epiphysis (SCFE/SUFE) in Paediatric Patients’ and to add it to the list of adverse drug reactions (ADRs) with frequency ‘Common’, based on a safety topic report. The Package Leaflet is updated accordingly.”

**Revestive - Teduglutide - EMEA/H/C/002345/II/0064, Orphan**
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Thalia Marie Estrup Blicher, ”Update of section 4.4 of the SmPC in order to add the recommendation of upper GI endoscopy or other imaging before and during the treatment with teduglutide per clinical discretion as a precaution to ‘Gastrointestinal neoplasia including hepatobiliary tract’ based on the cumulative review of literature. In addition, the MAH took the opportunity to introduce minor editorial changes and to bring the PI in
Reyataz - Atazanavir -
EMEA/H/C/000494/II/0139
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.3 and 4.5 of the SmPC in order to reclassify the drug-drug-interaction information to a contraindication for the co-administration with antineoplastic agents (encorafenib and ivosidenib), as well as, for the co-administration with the anticonvulsant agents (carbamazepine, phenobarbital, and phenytoin); based on post-marketing data and literature. The Package Leaflet is updated accordingly."

Scemblix - Asciminib -
EMEA/H/C/005605/II/0013/G, Orphan
Novartis Europharm Limited, Rapporteur: Janet Koenig, "Grouped application comprising three type II variations as follows:
C.I.4 - Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with P-gp Substrates based on the final results from studies 2301078, CABL001A2301 and CABL001X2101, listed as a category 3 study in the RMP.
C.I.4 - Update of section 4.8 of the SmPC in order to update the Summary of the safety profile and safety information based on final results from study CABL001A2301 and CABL001X2101, listed as a category 3 study in the RMP.
C.I.4 - Update of section 5.1 of the SmPC in order to update safety information based on final results from study CABL001A2301. The Package Leaflet is updated accordingly."

Uptravi - Selexipag -
EMEA/H/C/003774/II/0042/G
Janssen-Cilag International N.V., Rapporteur: Martina Weise, "A grouped application comprised of 3 Type II variations as follows:
C.I.4: Update of sections 4.2 and 5.2 of the SmPC in order to update pharmacokinetic information based on results from the paediatric PK study AC-065A203; this is a phase 2 multicenter, open-label, single-arm study to evaluate the safety, tolerability and pharmacokinetics of selexipag in children from 2 years to less than 18 years of age with pulmonary arterial hypertension (PAH)."
C.I.4: Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information based on results from study AC-065A310 (SALTO); this is a phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel group study with open-label extension period to assess the efficacy and safety of selexipag as add-on to standard of care in children from 2 years to less than 18 years of age with pulmonary arterial hypertension (PAH).

C.I.4: Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy information based on results from the pharmacodynamic (PD) similarity/comparison study to compare the PD and clinical responses for efficacy based on study AC-065A203, study AC-065A310 and study AC-065A302 in paediatric participants from 2 years to less than 18 years of age and adult participants with PAH.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information.

---

**Veklury - Remdesivir -**
**EMEA/H/C/005622/II/0056**
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC in order to update antiviral activity information based on the final results from the nonclinical study PC-540-2048 on the antiviral activity of remdesivir against SARS-CoV-2 Omicron XBF, XBB.1.16, FL.22, XBB.2.3.2, EG.5.1, EG.1.2, BA.2.86 and XBB.1.9.2 subvariants."

---

**VELCADE - Bortezomib -**
**EMEA/H/C/000539/II/0102**
Janssen-Cilag International N.V., Rapporteur: Paolo Gasparini, "Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy and preclinical clinical information following EMA/CHMP/SWP/74077/2020 rev. 1* dated 30 March 2023. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3."

---

**Venclyxto - Venetoclax -**
**EMEA/H/C/004106/II/0048**
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to
update safety and efficacy information on paediatric population following the assessment of procedure P46/018 based on final results from study M13-833 - A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies. The Package Leaflet is updated accordingly.”

**Verzenios - Abemaciclib - EMEA/H/C/004302/II/0033**

Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to include the final OS data based on final results from study MONARCH3 (I3Y-MC-JPBM). This is a randomized, double-blind, placebo-controlled, phase 3 trial of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 Inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-Negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting.”

**WS2612**

Finlee-EMEA/H/C/005885/WS2612/0003

Mekinist-EMEA/H/C/002643/WS2612/0062

Spexotras-EMEA/H/C/005886/WS2612/0001

Tafinlar-EMEA/H/C/002604/WS2612/0065

Novartis Europharm Limited, Lead Rapporteur: Peter Mol, “Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Tumour lysis syndrome and add Tumour lysis syndrome to the list of adverse drug reactions (ADRs) with frequency Not known based on the review of MAH global database, clinical trials database and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3 and to introduce editorial changes.”

**WS2650**

Imfinzi-EMEA/H/C/004771/WS2650/0065

IMJUDO-EMEA/H/C/006016/WS2650/0006

AstraZeneca AB, Lead Rapporteur: Aaron Sosa Mejia, “Update of sections 4.2 and 4.4 of the SmPC in order to simplify current dosing
B.6.10. CHMP-PRAC assessed procedures

Akeega - Niraparib / Abiraterone acetate - EMEA/H/C/005932/II/0003
Janssen-Cilag International N.V., Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.8 and 5.1 of the SmPC in order to update the frequency of adverse drug reactions and to update information from MAGNITUDE study based on final results from study 64091742PCR3001 (MAGNITUDE) listed as a PAES in the Annex II. This is a phase 3 randomized, placebo-controlled, double-blind, multicenter study which assessed the efficacy and safety of niraparib 200 mg in combination with AA 1,000 mg once daily plus prednisone or prednisolone 10 mg daily (AAP)a, compared with placebo plus AAP in men with mCRPC and HRR gene alterations, approximately half of whom had BRCA gene alterations and comprised the prespecified BRCA subgroup. The Annex II and Package Leaflet are updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took this opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI."

Eylea - Aflibercept - EMEA/H/C/002392/II/0090
Bayer AG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety and clinical information based on results from studies PULSAR (20968) and PHOTON (21091). PULSAR (20968) is an ongoing pivotal Phase 3 study to investigate the efficacy and safety of HD aflibercept at treatment intervals of 12 weeks and longer for indication neovascular age-related macular degeneration (nAMD). PHOTON (21091), is an ongoing pivotal Phase 2/3 study to investigate the efficacy and safety of HD aflibercept at treatment intervals of 12 weeks and longer for indication Diabetic Macular Edema (DME). The Package Leaflet is updated accordingly. The RMP version 34.1 has also been submitted. In
addition, the MAH took the opportunity to implement an editorial update in section 6.6 of the SmPC to align the text with other similar products.”

**Inrebic - Fedratinib -**  
**EMEA/H/C/005026/II/0020, Orphan**  
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol, PRAC Rapporteur: Sonja Hrabcik,  
"Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update information regarding thiamine levels based on a review of the primary results of the study FEDR-MF-002. This is a Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared with BAT in subjects with DIPSS intermediate-2 or high-risk primary MF, post-PV MF, or post-ET MF and previously treated with ruxolitinib. The RMP version 3 has also been submitted.”

**Orkambi - Lumacaftor / Ivacaftor -**  
**EMEA/H/C/003954/II/0088**  
Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Eamon O Murchu, "Submission of the final report from study VX19-809-124 (study 124), listed as a category 3 study in the RMP. This is a Phase 3, open-label, rollover study to evaluate the long-term safety and tolerability of lumacaftor/ivacaftor in cystic fibrosis subjects homozygous for F508del who were 1 to <2 years of age at treatment initiation and who completed the Safety Follow Up (SFU) visit in study 122 (Part B) or were lumacaftor/ivacaftor naive. The RMP version 11.5 has also been submitted.”

**Phesgo - Pertuzumab / Trastuzumab -**  
**EMEA/H/C/005386/II/0023/G**  
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Gabriele Maurer,  
“A grouped application comprised of 2 Type II variations and 1 Type IA variation, as follows: Type II variation (C.I.4): Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information, based on the final report from study WO40324 (FeDeriCa) listed as a category 3 study in the RMP. This is a phase 3, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous..."
administration of the fixed-dose combination of pertuzumab and trastuzumab in combination with chemotherapy in patients with HER2-positive early breast cancer.

Type II variation (C.1.4): Update of section 4.8 of the SmPC in order to only present specific Phesgo safety data by updating the summary of safety profile and the tabulated list of adverse reactions to reflect this information. The Package Leaflet is updated accordingly.

Type IA variation (A.6): To change the ATC code of pertuzumab and trastuzumab from L01XY02 to L01FY01.

The RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information and to update the list of local representatives in the Package Leaflet."

WS2670
Finlee-EMEA/H/C/005885/WS2670/0004
Spexotras-
EMEA/H/C/005886/WS2670/0003

Novartis Europharm Limited, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ulla Wändel Liminga, "To include into the product information for dabrafenib and trametinib the signal "peripheral neuropathy" in line with the PRAC recommended wording from EMA/PRAC/289010/2023, EPITT No. 19947."

B.6.11. PRAC assessed procedures

PRAC Led
Amlodipine-Valsartan Mylan - Amlodipine / Valsartan - EMEA/H/C/004037/II/0021
Mylan Pharmaceuticals Limited, Generic, Generic of Exforge, PRAC Rapporteur: Karin Erneholm, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 4.0 in order to align the safety concerns with the latest version of the RMP for Amlodipine/Valsartan available in the public domain and to bring the RMP in line with the latest RMP template."

PRAC Led
ASPAVELI - Pegcetacoplan -
EMEA/H/C/005553/II/0018, Orphan
Swedish Orphan Biovitrum AB (publ), PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP
liaison: Outi Mäki-Ikola, “Submission of an updated RMP version 2.1 in order to revise the category 3 PASS Sobi.PEGCET-301 and Sobi.PEGCET-302.”

PRAC Led

**Avamys - Fluticasone furoate - EMEA/H/C/000770/II/0051/G**

GlaxoSmithKline (Ireland) Limited, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, “Grouped application comprising two type II variations as follows:

- **C.I.11.b** – Submission of an updated RMP version 12 in order to remove Headache, Nasal events (including: epistaxis, nasal ulceration, nasal septum perforation and other nasal events), Hypersensitivity, Cataract and glaucoma as Important Identified Risks; to remove Taste and smell disorders, Pyrexia, Systemic corticosteroids effect: adrenal suppression, Systemic corticosteroid effect: growth retardation, Psychiatric effects as Important Potential Risks and to remove Use in pregnancy and lactation, Off-label use (sinusitis and children < 6 years of age) as missing information.

- **C.I.11.b** – Submission of an updated RMP version 12 in order to remove targeted follow up questionnaires.

In addition, the MAH took this opportunity to align the RMP template with GVP Module V Revision 2.”

PRAC Led

**Beovu - Brolucizumab - EMEA/H/C/004913/II/0028**

Novartis Europharm Limited, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC in order to add ‘Scleritis’ to the list of adverse drug reactions (ADRs) with frequency ‘Not known’, following the recommendation by PRAC in the outcome for the signal assessment of Scleritis. The Package Leaflet is updated accordingly.”

PRAC Led

**Cholestagel - Colesevelam - EMEA/H/C/000512/II/0053**

CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Bianca
Mulder, PRAC-CHMP liaison: Patrick Vrijlandt, 
"Submission of an updated RMP version 2.0 in 
order to remove important identified and 
potential risks, as well as missing information to 
bring it in line with GVP module V. Additionally, 
epidemiological data on indication and target 
population, clinical data and post-marking 
exposure data was updated."

PRAC Led

Efient - Prasugrel -
EMEA/H/C/000984/II/0037
Substipharm, Rapporteur: Thalia Marie Estrup 
Blicher, PRAC Rapporteur: Marie Louise 
Schougaard Christiansen, PRAC-CHMP liaison: 
Thalia Marie Estrup Blicher, "Submission of an 
updated RMP version 13 in order to remove of a 
region-specific additional risk-minimisation 
activity following previous PSUSA procedure 
(EMEA/H/C/PSUSA/00002499/202102), as well 
as to align content and format with new 
requirements according to GVP Module V Rev. 2. 
In addition, the MAH took the opportunity to 
update Annex II of the PI and to update the list 
of local representatives in the Package Leaflet."

PRAC Led

Lysodren - Mitotane -
EMEA/H/C/000521/II/0030
HRA Pharma Rare Diseases, PRAC Rapporteur: 
Maria del Pilar Rayon, PRAC-CHMP liaison: 
Carolina Prieto Fernandez, "Update of section 
4.4 of the SmPC in order amend an existing 
warning on hepatic impairment based on a 
cumulative review of cases with increase of 
transaminases >5 ULN and the outcome of 
these elevations after mitotane discontinuation, 
following the request by PRAC in the 
PSUSA/00002075/202304."

PRAC Led

Moventig - Naloxegol -
EMEA/H/C/002810/II/0043
Kyowa Kirin Holdings B.V., PRAC Rapporteur: 
Eamon O Murchu, PRAC-CHMP liaison: Finbarr 
Leacy, "Submission of the final report from the 
PASS study D3820R0008 listed as a category 3 
study in the RMP. This is a US post-marketing, 
comparative, observational study to evaluate 
the cardiovascular safety of Naloxegol in 
patients with non-cancer pain in comparison to 
other treatments for opioid induced
constipation. The RMP version 9.0 has also been submitted.”

PRAC Led
Remicade - Infliximab - EMEA/H/C/000240/II/0247
Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, “Submission of an updated RMP version 22.1 in order to remove reference to the immunogenicity substudy as part of protocol REMICADEPIB4002 in Part III. The MAH proposes to discontinue the Dutch portion of the immunogenicity substudy, which is part of protocol REMICADEPIB4002.”

PRAC Led
VidPrevtyn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754/II/0010
Sanofi Pasteur, PRAC Rapporteur: Jana Lukacisinova, PRAC-CHMP liaison: Petr Vrbata, “Submission of an updated RMP version 2.1 in order to update the list of safety concerns with the removal of Vaccine Associated Enhanced Disease (VAED) including Vaccine Associated Enhanced Respiratory Disease (VAERD) as an important potential risk. In addition, the MAH is taking the opportunity to change anaphylactic reaction risk characterization from potential to identified risk, to update clinical trial exposure (VAT00008 open label extension), to update signal detection and literature screening strategy, to update the CSR due dates for VAT00002 and VAT00008, to remove category 3 study VAT00006, to cancel category 3 study VAT00007, to discontinue category 3 study VAT00012, to cancel category 3 study VBA00003 following availability of UK HSA data and to update the adverse events of special interest (AESI) preferred terms list.”

PRAC Led
WS2671
Finlee-EMEA/H/C/005885/WS2671/0005
Spexotras-EMEA/H/C/005886/WS2671/0004
Tafinlar-EMEA/H/C/002604/WS2671/0067
Novartis Europharm Limited, Lead PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Eva Skovlund, "Update of section 4.8 of
the SmPC for Tafinlar, Finlee and Spexotras in order to add 'Atrioventricular (AV) block' and 'Bundle branch block' to the list of adverse drug reactions (ADRs), following the PRAC recommendation in the PSUR for Mekinist (PSUSA/00010262/202305). The Package Leaflet is updated accordingly.”

B.6.12. CHMP-CAT assessed procedures

ROCTAVIAN - Valoctocogene roxaparvovec
- EMEA/H/C/005830/II/0010, Orphan, ATMP
BioMarin International Limited, Rapporteur: Violaine Clossen Carella, CHMP Coordinator: Jean-Michel Race, “Submission of the final report from study BMN270-302 listed as a category 3 study in the RMP. This is a phase 3 open-label, single-arm study to evaluate the efficacy and safety of BMN 270, an adeno-associated virus vector–mediated gene transfer of human factor VIII at a dose of 4E13 vg/kg in hemophilia A patients with residual FVIII levels ≤ 1 IU/dL receiving prophylactic FVIII infusions.”

WS2646
Tecartus-
EMEA/H/C/005102/WS2646/0042
Yescarta-
EMEA/H/C/004480/WS2646/0073
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus,

B.6.13. CHMP-PRAC-CAT assessed procedures

WS2632
Tecartus-
EMEA/H/C/005102/WS2632/0041
Yescarta-
EMEA/H/C/004480/WS2632/0072
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, Lead PRAC Rapporteur: Karin Erneholm, "Update of sections 4.2 and 5.1 of the SmPC in order to update the safety monitoring timelines based on data from clinical studies, post-marketing studies and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to sections 2.2, 6.3 and 6.6 and to update sections 4.4 and 4.5 of
the SmPC to align the language across both products.”

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

<table>
<thead>
<tr>
<th>Code</th>
<th>Product</th>
<th>EMEA/H/C/Number</th>
<th>Lead Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS2639</td>
<td>Glyxambi-</td>
<td>EMEA/H/C/002279/WS2639/0072</td>
<td>Jentadueto-</td>
</tr>
<tr>
<td>WS2640</td>
<td>Infanrix hexa-</td>
<td>EMEA/H/C/000296/WS2640/0343</td>
<td>Glyxambi, Lead Rapporteur: Christophe Focke</td>
</tr>
<tr>
<td>WS2648/G</td>
<td>Miricera-</td>
<td>EMEA/H/C/00116/WS2648/0123/G</td>
<td>NeoRecormon-</td>
</tr>
</tbody>
</table>

Boehringer Ingelheim International GmbH, Lead Rapporteur: Patrick Vrijlandt

Trelegy Ellipta - EMEA/H/C/004363/WS2645/0036/G
GlaxoSmithKline Trading Services Limited, Lead Rapporteur: Finbarr Leacy

Roche Registration GmbH, Lead Rapporteur: Martina Weise
Organon N.V., Duplicate, Duplicate of Allex (SRD), Azomyr, Opulis (SRD), Lead Rapporteur: Christophe Focke, “To update section 4.4 of the SmPC and section 2 of the package leaflet to correct the content of benzyl alcohol from 0.75 mg to 0.375 mg and the content of propylene glycol from 100.75 mg to 100.19 mg to comply with the Annex to the European Commission guideline on “Excipients in the labelling and package leaflet of medicinal products for human use”.

In addition, the MAH has taken the opportunity to update section 4.8 of the SmPC and section 4 of the package leaflet to correct the link to QRD Appendix V for the national reporting system. Furthermore, the MAH has taken the opportunity to update the package leaflet with details of the local representative for Austria. Lastly, the MAH has taken the opportunity to introduce minor editorial corrections to the PI in the following language: CS.”
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)


B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

H. ANNEX H - Product Shared Mailboxes – e-mail address